# Antibiotic Treatment and Appendectomy for Uncomplicated Acute Appendicitis in Adults and Children

A Systematic Review and Meta-analysis

Mauro Podda, MD,\* Chiara Gerardi, Pharm D,† Nicola Cillara, MD,‡ Nicola Fearnhead, MD, FRCS,§ Carlos Augusto Gomes, MD, PhD,¶ Arianna Birindelli, MD,|| Andrea Mulliri, MD,\*\* Richard Justin Davies, M Chir, FRCS,§ and Salomone Di Saverio, MD, FRCS§

**Objective:** The aim of this meta-analysis was to summarize the current available evidence on nonoperative management (NOM) with antibiotics for uncomplicated appendicitis, both in adults and children.

**Summary Background Data:** Although earlier meta-analyses demonstrated that NOM with antibiotics may be an acceptable treatment strategy for patients with uncomplicated appendicitis, evidence is limited by conflicting results.

- From the \*Department of General, Emergency and Robotic Surgery, San Francesco Hospital, Nuoro, Italy; †Centro di Politiche Regolatorie del Farmaco, IRCCS – Istituto di Ricerche Farmacologiche "Mario Negri", Milano, Italy; †Department of Surgery, Santissima Trinità Hospital, Cagliari, Italy; \$Cambridge Colorectal Unit, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; ¶Department of Surgery, Hospital Universitario Terezinha de Jesus, Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil; ||Trauma Surgery Unit, Maggiore Hospital Regional Emergency Surgery and Trauma Center, AUSL Bologna Local Health District Bologna, Bologna, Italy; and \*\*Department of Digestive Surgery, University Hospital of Caen, Caen cedex, France.
- Contributions of authors: M.P.: Study conception and design, literature search, acquisition, interpretation and analysis of data; drafting and critically revising the article for important intellectual content; and final approval of the version to be published. C.G.: Study conception and design, literature search, acquisition, interpretation and analysis of data; drafting and critically revising the article for important intellectual content; and final approval of the version to be published. N.C.: Interpretation and analysis of data; drafting and critically revising the article for important intellectual content; and final approval of the version to be published. N.F.: Interpretation and analysis of data; critically revising the article for important intellectual content; and final approval of the version to be published. C.A.G.: Interpretation and analysis of data; critically revising the article for important intellectual content; and final approval of the version to be published. A.B.: Interpretation and analysis of data; critically revising the article for important intellectual content; and final approval of the version to be published. A.M.: Interpretation and analysis of data; critically revising the article for important intellectual content; and final approval of the version to be published. R.J.D.: Interpretation and analysis of data; drafting and critically revising the article for important intellectual content; editing and revising the English for the final version to be published; and final approval of the version to be published. S.D.S.: Study conception and design, literature search, acquisition, interpretation and analysis of data; drafting and critically revising the article for important intellectual content; Editing and revising the English for the final version to be published; and final approval of the version to be published.
- This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
- Ethical approval: No ethical approval was required for this article.

The authors report no conflicts of interest.

- Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.annalsofsurgery.com).
- Reprints: Dr. Mauro Podda, MD, Department of Surgery: General, Emergency and Robotic Surgical Unit, San Francesco Hospital, ASSL Nuoro, ATS Sardegna, Via Mannironi, 1, 08100 Nuoro, Italy. E-mail: mauropodda@ymail.com.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved. ISSN: 0003-4932/16/XXXX-0001

DOI: 10.1097/SLA.00000000003225

**Methods:** Systematic literature search was performed using MEDLINE, the Cochrane Central Register of Controlled Trials, and EMBASE databases for randomized and nonrandomized studies comparing antibiotic therapy (AT) and surgical therapy-appendectomy (ST) for uncomplicated appendicitis. Literature search was completed in August 2018.

**Results:** Twenty studies comparing AT and ST qualified for inclusion in the quantitative synthesis. In total, 3618 patients were allocated to AT (n = 1743) or ST (n = 1875). Higher complication-free treatment success rate (82.3% vs 67.2%; P < 0.00001) and treatment efficacy based on 1-year follow-up rate (93.1% vs 72.6%; P < 0.00001) were reported for ST. Index admission antibiotic treatment failure and rate of recurrence at 1-year follow-up were reported in 8.5% and 19.2% of patients treated with antibiotics, respectively. Rates of complicated appendicitis with peritonitis identified at the time of surgical operation (AT: 21.7% vs ST: 12.8%; P = 0.07) and surgical complications (AT: 12.8% vs ST: 13.6%; P = 0.66) were equivalent.

**Conclusions:** Antibiotic therapy could represent a feasible treatment option for image-proven uncomplicated appendicitis, although complication-free treatment success rates are higher with ST. There is also evidence that NOM for uncomplicated appendicitis does not statistically increase the perforation rate in adult and pediatric patients receiving antibiotic treatment. NOM with antibiotics may fail during the primary hospitalization in about 8% of cases, and an additional 20% of patients might need a second hospitalization for recurrent appendicitis.

Keywords: acute appendicitis, antibiotic therapy, appendectomy, conservative treatment, meta-analysis, nonoperative management, uncomplicated appendicitis

(Ann Surg 2019;xx:xxx-xxx)

A cute appendicitis remains one of the most common causes of an acute abdomen and is the commonest surgical disease among adult and pediatric patients presenting to emergency departments, both in the United States and Europe.<sup>1</sup>

In North America, the incidence is 100 per 100,000 personyears, with a stable trend throughout the latest decades of the 20th century. Although the disease was relatively uncommon outside Western countries during the 20th century, a rising incidence is reported from the beginning of the 21st century within newly industrialized countries.<sup>2</sup>

Since the first successful appendectomy was performed by Claudius Amyand in 1735 at St. George's Hospital in London, surgery has been the mainstay of treatment for over 2 centuries. Current evidence suggests laparoscopic appendectomy as the gold standard for surgical treatment, with lower incidence of wound infections, postintervention morbidity, shorter hospital stay, and higher quality of life scores when compared with open appendectomy.<sup>3</sup>

Although conservative management with antibiotics has been well established for intra-abdominal infections of other sources (in

Annals of Surgery • Volume XX, Number XX, Month 2019

www.annalsofsurgery.com | 1

particular, for uncomplicated acute sigmoid diverticulitis), nonoperative management (NOM) of uncomplicated appendicitis is still limited by conflicting results coming from recent studies with high risk of bias.<sup>4,5</sup>

To date, many randomized controlled trials and nonrandomized studies have promoted antibiotic therapy as a safe approach to appendectomy for adult patients with uncomplicated appendicitis, suggesting success rates as high as 90% at 30 days and 75% within 1 year of treatment.<sup>6–9</sup> More recently, results of NOM with antibiotics in children have confirmed that the conservative strategy is a safe and effective alternative to surgery, with 64% to 86% success rates, lower incidence of complications, and no differences in the rate of complicated appendicitis compared to appendectomy.<sup>10,11</sup>

However, the recently published Jerusalem Guidelines and separately the European Association of Endoscopic Surgery (EAES) guidelines, note inadequate evidence to recommend routine NOM, and so generally appendectomy remains the treatment of choice recommended in Europe and the United States.<sup>3,12</sup>

Despite earlier meta-analyses demonstrating that NOM with antibiotics may be an acceptable treatment strategy for patients with uncomplicated appendicitis, there is still a lack of evidence regarding effectiveness and safety, potential complications, duration of pain, costs, lengths of hospital stay and time to return to normal daily life activity following NOM.<sup>5,13–16</sup>

The aim of this systematic review and meta-analysis was to summarize and systematically review the current available evidence on the antibiotic approach to uncomplicated appendicitis both in adults and children.

#### METHODS

This systematic review and meta-analysis was conducted according to the recommendations of the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines,<sup>17</sup> the meta-analysis of observational studies in epidemiology checklist for observational studies (MOOSE),<sup>18</sup> and was specified in a registered protocol (PROSPERO: CRD42018104806). All stages of study identification, selection, quality assessment and data abstraction were carried out independently by 2 reviewers (M.P. and S.D.S.). Any discrepancies were resolved by consulting a third reviewer (C.G.).

### **Study Identification**

MEDLINE (via PubMed), the Cochrane Central Register of Controlled Trials, and EMBASE were systematically searched for relevant studies. Reference lists of relevant studies were searched manually and the "related articles" function in PubMed was used. The search strategy combined text words and MeSH terms related to antibiotic therapy (AT) versus appendectomy/surgical therapy (ST) of uncomplicated appendicitis in adults and children: [appendicitis, antibiotic, nonoperative treatment, conservative management, nonoperative management] and [appendicitis, appendectomy].

Corresponding search strategies were used for the Cochrane Central Register of Controlled Trials and EMBASE. No language restrictions were applied. Literature search was completed in August 2018.

The detailed search strategy is freely accessible in the protocol (PROSPERO: CRD42018104806).

# **Study Selection**

For sensitivity reasons, not only randomized controlled trials (RCTs) but also prospective cohort studies (PCSs) and retrospective cohort studies (RCSs) comparing AT and ST as primary treatment for

uncomplicated appendicitis in adults and children were included in the systematic review and meta-analysis. All studies eligible for inclusion had to report a clear definition of the diagnosis "uncomplicated acute appendicitis." Only studies that reported at least one of the primary outcome or secondary outcomes were included.

The exclusion criteria were: studies not reporting data on the selected outcomes of interest, or articles in which the outcomes of interest could not be calculated; studies not specifying the patients selection criteria; studies reporting on complicated appendicitis (gangrenous, perforated appendicitis with abscess or generalized peritonitis); studies not reporting the specific antibiotic treatment regimens used for the AT; non-human studies; studies that reported only percentages instead of absolute numbers or odds ratios; review articles; editorials; comments; letters and case reports. The 2 reviewers independently screened all studies retrieved from the search, and full text articles were obtained if inclusion criteria were fulfilled. Where there was overlap in patient cohorts of 2 studies, the most recent and largest study was included in the systematic review and meta-analysis.

#### **Risk of Bias Assessment**

The risk of bias for the studies enrolled in the systematic review and meta-analysis was assessed according to the Cochrane handbook for systematic reviews of interventions,<sup>19</sup> using the Cochrane risk of bias tool for RCTs, and the risk of bias in nonrandomized studies tool (ROBINS-I) for PCSs and RCSs.<sup>20</sup>

#### **Quality of Evidence Assessment**

The grading of recommendations assessment, development and evaluation (GRADE) methodology was applied for assessing quality of evidence, and reported in the results.<sup>21</sup>

## **Outcomes Measures**

- Primary outcome measures were evaluated to assess effectiveness and safety of AT and ST for uncomplicated appendicitis. The following outcomes were reviewed:
  - 1. Complication-free treatment success: success of the initial treatment (AT or ST) with an uncomplicated course (no postoperative complications, adverse events, or treatment failure occurring);
  - 2. Treatment efficacy based on 1-year follow-up (intention-to-treat analysis): efficacy for AT was defined as achieving a definitive improvement without requiring surgery within a median follow-up of 1 year. Lack of efficacy in the AT group included both persistence of acute appendicitis during the hospitalization (index admission AT failure: nonresolving appendicitis with persistent or worsening symptoms during the primary hospitalization) and recurrent acute appendicitis. On the other hand, efficacy for the ST was defined as uncomplicated appendicitis confirmed at the time of the surgical operation of symptoms after surgical treatment.
  - 3. Complicated appendicitis with peritonitis identified at the time of surgical operation: in the AT group the analysis was carried out within the cohort of patients who underwent appendectomy after the failure of the AT.
  - 4. Postintervention complications (intention-to-treat analysis): the number and rates of postoperative abscesses, surgical site infections, incisional hernias, obstructive symptoms, and other general complications, including adverse reaction to antibiotics, anesthesiology complications, cardiovascular and pulmonary adverse events were analyzed on an intention-totreat basis.

2 | www.annalsofsurgery.com

© 2019 Wolters Kluwer Health, Inc. All rights reserved.

- 5. Surgical complications: the number and rates of surgical complications only were analyzed both for patients who underwent ST as primary treatment and for those who underwent surgery as second line approach, after failure of AT treatment during the hospitalization, or for recurrent appendicitis.
- Secondary outcome measures were evaluated to assess other potential benefits and drawbacks of AT and ST in terms of:
  - 1. Number and rates of patients treated with a laparoscopic approach in both groups.
  - 2. Total costs: total medical and surgical costs for the primary hospital stay (primary costs), including materials, medications, radiology and surgical resources, pathology, laboratory tests). Costs were also analyzed for all appendicitis-related care (conservative treatment success or failure vs surgery without complications or surgery with complications). Currency conversion from original value to USD (United States Dollar) was made on August 15, 2018.
  - 3. Length of primary hospital stay: number of days of primary inpatient admission.
  - 4. Total length of stay per patient: number of days of hospitalization for readmissions added to the number of days of primary inpatient admission.
  - 5. Duration of pain (in days) following AT and ST.
  - 6. Length of sick leave (in days) following AT and ST.
  - 7. Length of time off work (in days) following AT and ST.
  - 8. Quality of life following AT and ST.

#### **Data Extraction**

The 2 reviewers independently reviewed each included article. A predefined paper-based sheet was used for data extraction.

Data collected for each article comprised the following predefined items: 1) Study identifier (first author, year of publication); 2) Essential study data (study period, study location, study population); 3) Study design (RCT, q-RCT, PCS, RCS); 4) Treatment arms and number of enrolled subjects; 5) Baseline characteristics of study subjects (mean age, sex, WBC count, body temperature, CRP concentration, Alvarado/AIR/PAS score on admission); 6) General characteristics of eligible studies (inclusion and exclusion criteria, sample size calculation, preintervention imaging techniques, treatment modalities, definition of the investigated primary and secondary outcomes); 7) Treatment outcomes, as described above.

# **Statistical Analysis**

The meta-analysis was conducted by searching for a numerical estimate of the outcome of interest.

Variables for pooled analysis were considered if they were previously evaluated by at least 2 studies. All statistical analyses were carried out using Reviewer Manager software (Review Manager-RevMan-version 5.3.5, 2014, The Nordic Cochrane Centre, Cochrane Collaboration, www.cochrane-handbook.org). Data entries in the columns of forest plots were double-checked individually by 2 reviewers to avoid errors. The odds ratio (OR) with 95% confidence interval (95% CI) was calculated for dichotomous variables, and the standardized mean difference (SMD) with 95% CI for continuous variables. When continuous data were presented as medians and range, the method by Hozo et al to estimate respective means and standard deviations was applied.<sup>22</sup> The point estimate of the OR value was considered statistically significant at P level of less than 0.05 if the 95% CI did not cross the value 1. The point estimate of the SMD value was considered statistically significant at P level of less than 0.05 if the 95% CI did not cross the value 0.

Heterogeneity of the results across studies was assessed using the Higgins'  $I^2$  and chi-square tests. A *P* value of chi-square test less than 0.10 with an  $I^2$  value of greater than 50% was considered indicative of substantial heterogeneity. Fixed-effects model (Mantel-Haenszel) was implemented if statistically significant heterogeneity was absent. Otherwise, a random-effects model was used for meta-analysis if statistically significant heterogeneity was found, according to the method of DerSimonian and Laird.<sup>23</sup>

Given that substantial differences in methodology and clinical settings were found among individual studies, subgroup analyses were planned with the aim of exploring interstudy heterogeneity (adults vs children and RCTs vs non-RCTs). Funnel plots were created to evaluate the risk of publication bias.

# RESULTS

A total of 8120 references were identified through database searching. Two more references were identified by searching lists of retrieved studies (Fig. 1).

Fifty-three full text publications were finally assessed for eligibility, of which 20 comparing AT and ST were included for quantitative synthesis. Seven of the included studies were randomized controlled trials (RCTs),<sup>6–10,24,25</sup> 8 were prospective cohort studies (PCSs),<sup>11,26–32</sup> 4 were retrospective cohort studies (RCSs),<sup>33–36</sup> and 1 was a quasirandomized study (q-RCT).<sup>37</sup> Ten studies were conducted in adults,<sup>6–9,24–26,31,36,37</sup> and 10 in children.<sup>10,11,27–30,32–35</sup> In total, 3618 patients were allocated to AT (n = 1743) or ST (n = 1875). General characteristics of patients as reported in the studies are shown in Table 1.

## Study Characteristics

Large heterogeneity was found among the included studies with regard to diagnostic criteria for uncomplicated appendicitis. Marked heterogeneity was also demonstrated in type of antibiotics administered, duration of administration, and different outcomes evaluated.

A single pediatric patient was enrolled in the otherwise adult population pilot study by Talan et al.<sup>9</sup> For this reason, running a minimal risk of selection bias, the trial was included among adult studies.

Hansson et al implemented quasi-randomization by date of birth. Patients, once randomized to a specific treatment, were allowed to cross-over and receive the alternative treatment based on their preference or medical judgment, resulting in cross-over (47.5% of patients in the AT group underwent surgery, and 7.8% in the ST group were finally treated conservatively with antibiotics).<sup>37</sup>

Mahida et al<sup>29</sup> assessed the feasibility of NOM with antibiotics only in children with an appendicolith identified on preintervention imaging. Poillucci et al<sup>36</sup> included 14 patients (8.7%) with a radiological diagnosis of complicated disease (phlegmon or abscess). The randomized pilot trial by Talan et al<sup>9</sup> evaluated safety and feasibility of a protocol allowing outpatient antibiotic management. This study was therefore excluded from the pooled analysis of length of hospitalization (Supp. Digit. Content. Tab. 1, http://links.lww.com/ SLA/B582).

# **Risk of Bias and Quality of Evidence Assessment**

Three of the 8 RCTs were judged at a low risk of bias,<sup>6,9,10</sup> 2 at high risk,<sup>25,37</sup> and 3 at unclear risk.<sup>7,8,24</sup> All but 3 trials<sup>24,25,37</sup> generated random sequence adequately and reported allocation concealment, resulting in a low risk of selection bias. None of the trials reported attempts at blinding patients, personnel, outcome assessors, or data analysts. None of the trials were considered at high risk of selective reporting and incomplete outcome data, as

© 2019 Wolters Kluwer Health, Inc. All rights reserved.

www.annalsofsurgery.com | 3




FIGURE 1. The PRISMA flow diagram for search and selection of articles included in the systematic review and meta-analysis.

primary endpoints were clearly defined and reported in each study (Supp. Digit. Content. Tab. 2, http://links.lww.com/SLA/B582). Four of the 10 non-RCTs were considered at serious risk of bias according to the ROBINS-I tool, <sup>11,29,33,34</sup> whereas the remaining 6 were judged at low or moderate risk (Supp. Digit. Content. Tab. 2, http://links.lww.com/SLA/B582). Graphically, potential publication bias was present for the following outcomes of interest: complication-free treatment success, treatment efficacy based on 1-year follow-up, postintervention complications, surgical complications, complicated appendicitis with peritonitis identified at the time of surgical operation, and length of primary hospital stay. Funnel plots have been provided as supplemental digital content (Supp. Digit. Content. Fig. 1, http://links.lww.com/SLA/B582). Overall quality of evidence, according to the GRADE criteria, was moderate for complication-free treatment success, treatment efficacy based on 1-year follow-up, postintervention complications, length of sick leave, and length of time off work. Surgical complications, length of primary hospital stay, duration of pain, and total costs had a low quality of evidence, whereas outcome results for intraoperative finding of complicated appendicitis with peritonitis were judged as very low (Table 2).

### Complication-free Treatment Success

Overall, 20 studies reported the rate of complication-free treatment success (Table 3). The study by Koike et  $al^{34}$  did not report the results in the ST group, and so, the pooled analysis

included 19 studies. Taking into account any type of postinterventional complications (including treatment failure), a significantly higher success rate was reported for ST: 82.3% for ST versus 67.2% for AT (sample size: 3374; OR 0.30; 95% CI 0.20–0.47; P <0.00001;  $I^2 = 77\%$ ). Subgroup analyses of the outcome revealed no significant difference between adults (sample size: 2767; AT: 68.7% vs ST: 80.9%; OR 0.37; 95% CI 0.22–0.63; P = 0.0003;  $I^2 =$ 84%) and children (sample size: 607; AT: 60.3% vs ST: 88.9%; OR 0.21; 95% CI 0.10–0.44; P < 0.0001;  $I^2 = 51\%$ ; test for subgroup differences: P = 0.21;  $I^2 = 35.5\%$ ) and between RCTs (sample size: 1800; AT: 65.7% vs ST: 79.6%; OR 0.30; 95% CI 0.15–0.58; P =0.0004;  $I^2 = 82\%$ ) and n-RCTs (sample size: 1574; AT: 68.7% vs ST: 86.1%; OR 0.30; 95% CI 0.16–0.56; P < 0.0001;  $I^2 = 77\%$ ; test for subgroup differences: P = 0.96;  $I^2 = 0\%$ ) (Fig. 2).

#### Treatment Efficacy Based on 1-year Follow-up

Data from 19 studies were included in the pooled analysis investigating the treatment efficacy based on 1-year follow-up (Table 3).

A significantly higher success rate was reported for ST: 93.1% versus 72.6% for AT (sample size: 3374; OR 0.12; 95% CI 0.06–0.24; P < 0.00001;  $I^2 = 81\%$ ). Subgroup analyses of the outcome revealed no significant difference between adults (sample size: 2767; AT: 73.6% vs ST: 91.9%; OR 0.18; 95% CI 0.08–0.41; P < 0.0001;  $I^2 = 88\%$ ) and children (sample size: 607; AT: 68.1% vs ST: 98.1%; OR 0.08; 95% CI 0.04–0.16; P < 0.00001;  $I^2 = 0\%$ ; test for

4 | www.annalsofsurgery.com

© 2019 Wolters Kluwer Health, Inc. All rights reserved.

	Study	Study	Study	Study	Patie	nts N.	Sex	(M:F)	Age— Mean	Years: ± SD	WBC (× 10 Mean ± SI sid	<sup>9</sup> /L):	Tempe Mean ± Si	ody rature: D —Admis- on	Concer	RP ntration Mean ± Imission	PAS Scor	or AIR of re: Mean ± dmission
Study	Туре	Period	Location	Population	Α	s	А	s	А	s	А	s	А	s	А	s	А	s
Eriksson S 1995	RCT	1992-1994	Sweden	Adults	20	20	14:6	13:7	$27.8 \pm 10.1$	$35\pm16.1$	$13.8\pm4.4$	$13.9\pm4.1$	$37.2\pm0.7$	$37.1\pm0.7$	$41\pm 30$	$40\pm 38$	NR	NR
Styrud J 2006	RCT	1996-1999	Sweden	Adults	128	124	128:0	124:0	NR	NR	$12.5\pm3.8$	$12.4\pm3.5$	$37.5\pm0.7$	$37.4\pm0.8$	$55\pm44$	$54\pm49$	NR	NR
Hansson J 2009	q-RCT*	2006-2007	Sweden	Adults	119	250	62:57	138:112	$40\pm2$	$37 \pm 1$	$12.2\pm0.4$	$13.5\pm0.3$	$37.2\pm0.1$	$37.5\pm0.1$	$51\pm5$	$56\pm3$	NR	NR
Turhan AN 2009	RCT	2005-2006	Turkey	Adults	107	183	65:42	125:58	$30.9 \pm 1.3$	$26.2\pm0.7$	NR	NR	NR	NR	NR	NR	$6.5\pm0.1$	$6.4 \pm 0.1$
Vons C 2011	RCT	2004-2007	France	Adults	119	120	73:47	70:49	$31\pm9$	$34\pm12$	$13.6\pm3.6$	$13.1\pm3.4$	NR	NR	NR	NR	NR	NR
Armstrong J 2014	RCS	2012-2013	Canada	Children	12	12	4:8	6:6	$12.2\pm4.2$	$12\pm3.2$	$16.1\pm4.4$	$14.0\pm4.2$	NR	NR	$13.6\pm26.8$	$54\pm23.4$	NR	NR
Koike Y 2014	RCS	2004-2010	Japan	Children	130	114	66:59	NR	$7.0\pm4.0$	NR	$12.5\pm4.0$	NR	NR	NR	$26.6\pm0.8$	NR	$8.2\pm0.2$	NR
Park HC 2014	PCS	2010-2011	Korea	Adults	119	159	57:62	86:73	$36.7 \pm 14.1$	$38.4 \pm 13.8$	$11.5\pm3.8$	$12.1\pm4.1$	$37.5\pm1$	$37.8 \pm 1.1$	$41.2\pm48.3$	$46.3\pm49.5$	$6.9\pm1$	$7.0\pm1$
Minneci PC 2015	PCS	2012-2013	USA	Children	37	65	24:13	45:20	$11\pm1.1$	$12\pm1.1$	$12.9\pm1.6$	$12.9\pm1.3$	NR	NR	NR	NR	NR	NR
Salminen P 2015	RCT	2009-2012	Finland	Adults	257	273	155:102	174:99	$33\pm 6.1$	$35\pm5.4$	$11.7\pm3.9$	$12\pm4$	NR	NR	$29\pm15$	$36\pm13.5$	NR	NR
Svensson JF 2015	RCT	2012-2012	Sweden	Children	24	26	14:10	12:14	$12.2\pm2.6$	$11.1\pm2.4$	$14.0\pm4.0$	$14.5\pm6.4$	$37.3\pm0.7$	$37.5\pm0.6$	$30.5\pm53.1$	$27.0\pm50.2$	NR	NR
Hartwich J 2016	PCS	2012-2014	USA	Children	24	50	14:11	30:19	$12.6\pm0.6$	$12.1\pm0.5$	$15.2\pm0.9$	$15.3\pm0.5$	NR	NR	NR	NR	NR	NR
Mahida JB 2016	$PCS^{\dagger}$	2014-2015	USA	Children	5	9	1:4	5:4	$14\pm0.1$	$11\pm1.7$	$13.8\pm1.8$	$14.3\pm0.3$	NR	NR	NR	NR	NR	NR
Tanaka Y 2016	PCS	2007-2013	Japan	Children	78	86	52:26	61:25	$10.1\pm2.0$	$10.4\pm2.3$	$14.7\pm3.7$	$15.3\pm3.8$	NR	NR	$47\pm48$	$61\pm57$	NR	NR
Allievi N 2017	PCS	2011-2015	Italy	Adults	284	109	135:149	59:50	$36.8 \pm 16.6$	$39.6 \pm 15.9$	$13.0\pm4.0$	$13.8\pm4.2$	NR	NR	$52.9\pm4.2$	$65.2\pm5.0$	$6.2\pm1.6$	$6.8 \pm 1.8$
Gorter RR 2017	PCS	2012-2014	Netherlands	Children	25	19	15:10	14:5	$14\pm2.0$	$14\pm2.8$	$12.0\pm3.7$	$12.0\pm4.9$	NR	NR	$35\pm32$	$30\pm 54.2$	NR	NR
Lee SL 2017	PCS	2015-2016	USA	Children	51	32	30:21	17:15	$10\pm1.7$	$11\pm2.0$	$13\pm1.4$	$14\pm2.0$	$37.5\pm0.3$	$37.2\pm0.3$	NR	NR	$7\pm0.8$	$7\pm0.6$
Mudri M 2017	RCS	2012-2015	UK	Children	26	26	7:19	18:8	12	11	NR	NR	NR	NR	NR	NR	NR	NR
Poillucci G 2017	RCS	2014-2016	Italy	Adults	162	184	63:99	86:98	$33.6\pm16.5$	$35.8\pm17.2$	NR	NR	NR	NR	NR	NR	$6.1\pm1.3$	$6.9 \pm 1.9$
Talan DA 2017	RCT	2015-2015	USA	Adults	16	14	9:7	9:5	$31\pm18.4$	$36\pm11.8$	$14.2\pm3.7$	$15.3\pm4.3$	$36.8\pm0.3$	$36.9\pm0.5$	$25.9\pm57.4$	$64.8\pm71.6$	$8\pm1.7$	$8 \pm 1.7$
Total					1.743	1.875	988:752	1.092:667	$21.8 \pm 11.6$	$23.4 \pm 12.4$	$13.3\pm1.2$	$13.6\pm1.1$	$37.2\pm0.2$	$37.3\pm0.2$	$\textbf{37.3} \pm \textbf{12.8}$	$48.5\pm13.6$	NA	NA

A indicates antibiotic group; AIR, appendicitis inflammatory response; NA, not applicable; NR, not reported; PAS, pediatric appendicitis score; PCS, prospective cohort study; q-RCT, quasi-randomized controlled trial; RCS, retrospective cohort study; RCT, randomized controlled trial; S, surgery group; SD, standard deviation.

\*Per-protocol analysis.

†Uncomplicated acute appendicitis with appendicolith.

Quality Assessment         f       Risk of       Parameterics         fs       Study Design       Bias       Inconsistency       Indirectness       Imprecision         7       RCTs, 1 q-RCT       Serious       Serious       Not serious       Not serious         7       RCTs, 1 q-RCT       Serious       Not serious       Not serious         6       RCTs, 1 q-RCT       Serious       Not serious       Serious         6       RCTs, 1 q-RCT       Serious       Not serious       Serious         6       RCTs, 1 q-RCT       Serious       Serious       Not serious         6       RCTs, 1 q-RCT       Serious       Serious       Not serious         7       RCTs, 1 q-RCT       Serious       Not serious       Serious         7       RCTs, 1 q-RCT       Serious       Not serious       Serious         7       RCTs, 1 q-RCT       Serious       Not serious       Serious       Not serious         7       RCTs, 1 q-RCT       Serious       Not serious       Not serious       Serious       Not serious         7       RCTs, 1 q-RCT       Serious       Not serious       Not serious       Not serious         7       RCTs							4		
					Quá	dity Assessme	UL		
ment success818007 RCTs, 1 q-RCTSeriousSeriousNot seriousNot seriousSerioused on 1-yr follow-up818007 RCTs, 1 q-RCTNot seriousNot seriousNot seriousSeriousSerioused on 1-yr follow-up818007 RCTs, 1 q-RCTNot seriousNot seriousSeri		No. of Studies	No. of Patients			Indirectness	Imprecision	Publication Bias	Publication Overall Quality Bias of Evidence <sup>*</sup>
ed on 1-yr follow-up       8       1800       7 RCTs, 1 q-RCT       Not serious       Not serious       Not serious       Not serious       Not serious       Not serious       Serious       Not serious       Not serious       Not serious       Not serious       Not seriou	Complication-free treatment success	~	1800		Serious	Not serious	Not serious	Serious	Moderate
f complicated appendicitis with peritonitis 7 1192 6 RCTs, 1 q-RCT Serious Ser	Treatment efficacy based on 1-yr follow-up	8	1800			Not serious	Not serious	Serious	Moderate
ications717506 RCTs, 1 q-RCTSeriousNot seriousNot seriousSeriou	Intraoperative finding of complicated appendicitis with peritonitis	7	1192	1 q-RCT	Serious	Serious	Serious	Serious	Very low
711496 RCTs, 1 q-RCTSeriousSeriousNot seriousSerious717706 RCTs, 1 q-RCTSeriousSeriousNot seriousNot seriousNot serious26081 RCT, 1 q-RCTSeriousSeriousNot seriousNot seriousNot serious311512 RCTs, 1 q-RCTSeriousSeriousNot seriousNot seriousNot seriousk24912 RCTsSeriousNot seriousNot seriousNot seriousNot serious	Postintervention complications	7	1750	1 q-RCT	Serious	Not serious	Not serious	Serious	Moderate
oital stay717706 RCTs, 1 q-RCTSeriousSeriousNot seriousNot seriousNot seriousNot serious26081 RCT, 1 q-RCTSeriousSeriousNot seriousNot seriousNot seriousSerious311512 RCTs, 1 q-RCTSeriousSeriousNot seriousNot seriousNot seriousNot seriousNot seriousk24912 RCTsSeriousNot seriousNot seriousNot seriousNot seriousNot serious	Surgical complications	7	1149	1 q-RCT	Serious	Serious	Not serious	Serious	Low
2     608     1 RCT, 1 q-RCT     Serious     Not serious     Not serious     Serious       3     1151     2 RCTs, 1 q-RCT     Serious     Serious     Not serious     Not serious       2     491     2 RCTs     Serious     Not serious     Not serious     Not serious     Not serious	Length of primary hospital stay	7	1770		Serious	Serious	Not serious	Not serious	Low
3     1151     2 RCTs, 1 q-RCT     Serious     Not serious     Not serious     Not serious       2     491     2 RCTs     Serious     Not serious     Not serious     Not serious	Duration of pain	2	608		Serious	Not serious	Not serious	Serious	Low
2 491 2 RCTs Serious Not serious Not serious Not serious Not serious	Length of sick leave	3	1151		Serious	Not serious	Not serious	Not serious	Moderate
	Length of time off work	2	491		Not serious	Not serious	Not serious	Not serious	Moderate
2 RCTs, 1 q-RCT Serious Serious Serious Not serious Not serious	Total costs (successful treatment)	с	449		Serious	Serious	Not serious	Not serious	Low

Annals of Surgery • Volume XX, Number XX, Month 2019

subgroup differences: P = 0.13;  $I^2 = 57.0\%$ ) and between RCTs (sample size: 1800; AT: 73.8% vs ST: 94.7%; OR 0.12; 95% CI 0.05-0.26; P < 0.00001;  $I^2 = 67\%$ ) and n-RCTs (sample size: 1574; AT: 71.6% vs ST: 90.8%; OR 0.12; 95% CI 0.04–0.35; *P* < 0.0001;  $I^2 = 85\%$ ; Test for subgroup differences: P = 0.95;  $I^2 = 0\%$ ) (Fig. 3). All the studies but that by Park et al<sup>26</sup> reported the rate of index admission antibiotic treatment failure. This was 8.5%. Overall, the rate of recurrence at 1-year follow-up was 19.2%. Laparoscopic appendectomy rates were reported by 8 authors in the AT group<sup>8,10,27,32,33,35,36</sup> and by 14 authors in the ST group<sup>7–10,25,27,30–33,35,36</sup> (Supp. Digit. Content. Tab. 3, http://links.lww.com/SLA/B582). However, only 2 studies were eligible for the quantitative analysis.<sup>8,36</sup> Results indicated that no significant difference in the rate of laparoscopic appendectomy was present between the group of patients submitted to surgery as first-line treatment and those who underwent surgery after failure of NOM with antibiotics (sample size: 624; AT: 54.2% vs ST: 77.4%; OR 0.31; 95% CI 0.06–1.55; P = 0.16;  $I^2 = 87\%$ ).

# Intraoperative Finding of Complicated Appendicitis With Peritonitis

Three studies did not report data on this outcome,  $^{28,31,34}$  and 3 studies did not report any such event.<sup>9,33,35</sup> The meta-analysis was conducted on 14 studies.<sup>6-8,11,24-27,29,30,32,36</sup> All studies, except Turhan et al<sup>25</sup> (based on intraoperative observation alone) reported the incidence of complicated appendicitis by histologic examination. Overall, it was 21.7% for AT versus 12.8% for ST (sample size: 1868; OR 2.01; 95% CI 0.93–4.34; P = 0.07;  $I^2 = 71\%$ ). The odds ratio for complicated appendicitis was doubled for patients in the AT group undergoing surgery following failure of NOM. However, the difference was not statistically significant. Subgroup analyses revealed no significant differences between adults (sample size: 1583; AT: 21.8% vs ST: 12.7%; OR 2.63; 95% CI 0.98–7.09; P < 0.00001;  $I^2 = 81\%$ ) and children (sample size: 285; AT: 20.1% vs ST: 13.9%; OR 1.17; 95% CI 0.35–3.88; P = 0.80;  $I^2 = 30\%$ ; Test for subgroup differences: P = 0.31;  $I^2 = 4.7\%$ ) and between RCTs (sample size: 1192; AT: 22.9% vs ST: 11.6%; OR 2.96; 95% CI 0.91–9.60; *P* = 0.0002;  $I^2 = 77\%$ ) and n-RCTs (sample size: 676; AT: 19.6% vs ST: 14.9%; OR 1.30; 95% CI 0.52–3.21; P = 0.58;  $I^2 = 49\%$ ; Test for subgroup differences: P = 0.28;  $I^2 = 15.9\%$ ) (Table 3) (Supp. Digit. Content. Fig. 2, http://links.lww.com/SLA/B582).

# **Postintervention Complications**

All studies except Koike et al<sup>34</sup> reported the rate of postintervention complications. Three studies<sup>10,28,29</sup> did not observe any such adverse events, whereas Allievi et al<sup>31</sup> reported the postintervention complications rate only for patients in the ST group. The meta-analysis was conducted on the remaining 15 studies. Overall, the rate of complications of AT was significantly lower compared to ST (sample size: 2843; AT: 7.1% vs ST: 14.5%; OR 0.41; 95% CI 0.22-0.77; P = 0.006;  $I^2 = 68\%$ ). Subgroup analyses revealed that the postintervention complications rate was statistically higher in the ST group limited to the adult population (sample size: 2374; AT: 6.6% vs ST: 14.5%; OR 0.39; 95% CI 0.16–0.94; P = 0.04;  $I^2 =$ 80%), but not in children (sample size: 469; AT: 9.6% vs ST: 12.5%; OR 0.57; 95% CI 0.28–1.16; P = 0.12;  $I^2 = 0\%$ ), although no significant differences were found between the two subgroups (test for subgroup differences: P = 0.53;  $I^2 = 0\%$ ).

AT was associated with a significantly lower rate of complications in non-RCT studies (sample size: 1750; AT: 5.3% vs ST: 12.1%; OR 0.31; 95% CI 0.15–0.65; P = 0.002;  $I^2 = 28\%$ ) but not in RCTs (sample size: 1093; AT: 8.2% vs ST: 15.9%; OR 0.55; 95% CI 0.21–0.45; P = 0.22;  $I^2 = 81\%$ ). The test for subgroup difference indicated that the design of the study did not modify the effect of

6 www.annalsofsurgery.com

© 2019 Wolters Kluwer Health, Inc. All rights reserved.

Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

TABLE 3. Summary of Primary Outcomes (Complication-free Treatment Success, Treatment Efficacy Based on 1-yr Follow-up, Intraoperative Finding of Complicated Appendicitis With Peritonitis, Postintervention Complications, Surgical Complications)

	Treatmen	ation-free at Success. %)*	on 1-yr Foll	fficacy Based ow-up (ITT). %)†	ing of Co Appendi	ative Find- omplicated acitis With is. N (%)‡	Complicat	ervention tions (ITT). (%)	Compl	gical ications. (%)‡
Study	Α	S	Α	S	Α	S	Α	S	Α	S
Eriksson S 1995	13 (65)	18 (90)	13 (65)	20 (100)	1 (14.3)	1 (5)	_	2 (10)	_	2 (10)
Styrud J 2006	93 (72.6)	107 (86.3)	97 (75.8)	120 (96.8)	12 (38.7)	6 (5)	4 (3.1)	17 (13.7)	4 (12.9)	17 (13.7)
Hansson J 2009	57 (47.9)	143 (57.2)	93 (78.2)	223 (89.2)	6 (26)	50 (20)	36 (30.2)	80 (32)	6 (26)	74 (29.6)
Turhan AN 2009	82 (76.6)	175 (95.6)	87 (81.3)	183 (100)	_	31 (16.9)	5 (4.7)	8 (4.4)	5 (26.3)	8 (4.4)
Vons C 2011	63 (52.9)	114 (95)	75 (63)	117 (97.5)	12 (27.2)	21 (18)	12 (10.1)	3 (2.5)	12 (27.3)	3 (2.5)
Armstrong J 2014	7 (58.3)	10 (83.3)	8 (66.7)	12 (100)	_	_	1 (8.3)	2 (16.7)	1 (25)	2 (16.7)
Koike Y 2014	105 (78.3)	NR	105 (78.3)	NR	NR	NR	NR	NR	NR	NR
Park HC 2014	95 (79.8)	136 (85.5)	96 (80.6)	152 (95.5)	4 (20)	11 (6.9%)	1 (0.8)	16 (10)	1 (5)	16 (10)
Minneci PC 2015	28 (75.7)	56 (86.2)	28 (75.7)	61 (93.8)	1 (11.1)	8 (12.3)	_	5 (7.7)	_	5 (7.7)
Salminen P 2015	180 (70)	209 (76.5)	186 (72.4)	254 (93)	14 (16.5)	2 (0.7)	6 (2.3)	45 (16.5)	6 (8.6)	45 (16.5)
Svensson JF 2015	18 (75)	26 (100)	18 (75)*	26 (100)*	_	5 (19.2)	_	_	_	_
Hartwich J 2016	17 (70.8)	50 (100)	17 (70.8)	50 (100)	NR	NR	_	_	_	_
Mahida JB 2016	2 (40)	9 (100)	2 (40)	9 (100)	_	6 (66.7)	_	_	_	_
Tanaka Y 2016	55 (70.5)	84 (97.7)	55 (70.5)	86 (100)	1 (7.1)	_	_	2 (2.3)	_	2 (2.3)
Allievi N 2017	232 (81.7)	89 (81.6)	232 (81.7) <sup>§</sup>	78 (71.5) <sup>§</sup>	NR	NR	NR	20 (18.3)	NR	20 (18.3)
Gorter RR 2017	9 (36)	8 (42.1)	21 (84)	19 (100)	_	4 (21)	12 (48)	11 (57.9)	_	2 (10.5)
Lee SL 2017	17 (33.3)	25 (78.1)	26 (50.9)	31 (96.8)	8 (50)	10 (31.2)	9 (18)	6 (19)	3 (12.5)	6 (19)
Mudri M 2017	17 (65.4)	21 (80.7)	17 (65.4)	25 (96.1)	_	_	_	4 (15.4)	_	4 (15.4)
Poillucci G 2017	87 (53.7)	159 (86.4)	87 (53.7)*	159 (86.4)*	10 (29.4)	44 (23.8)	4 (2.5)	25 (13.6)	4 (7.1)	25 (13.6)
Talan DA 2017	13 (81.2)	12 (85.7)	14 (87.5)	14 (100)	_	-	1 (6.2)	2 (14.3)	-	2 (14.3)
Total	1.190 (67.2)	1.451 (82.3)	1.277 (72.6)	1.639 (93.1)	69 (21.7)	199 (12.8)	91 (7.1)	248 (14.5)	42 (12.8)	233 (13.6)

\*Success of the initial treatment with uncomplicated course (no postoperative complications, adverse events, or treatment failure occurring).

†If not otherwise specified, efficacy means clinical recovery without need for surgical treatment at 1-year follow-up in the antibiotic group, and positive diagnosis of acute appendicitis during operation and resolution of symptoms after surgical treatment in the surgery group.

‡In the antibiotic group, after failure of the primary treatment and subsequent surgery.

\$In the antibiotic group the failure rate was intended as the necessity of appendectomy during index admission (acute failure) or a new episode of suspected appendicitis requiring surgical treatment within 1 year from discharge (delayed failure).

A indicates antibiotic group; CT, computed tomography; ITT, intention-to-treat analysis; NR, not reported; NA, not applicable; S, surgery group; US, ultrasound scan.

interventions (P = 0.37;  $I^2 = 0\%$ ) (Table 3) (Supp. Digit. Content. Fig. 3, http://links.lww.com/SLA/B582).

### Surgical Complications

Nineteen of 20 studies reported data on surgical complications. Allievi et al<sup>31</sup> reported the surgical complications rate only for patients in the ST group. Koike et al did not provide results for this outcome of interest.<sup>34</sup> Three studies<sup>10,28,29</sup> did not observe any adverse events. The pooled analysis involved 15 studies. Overall, the rates of surgical complications after AT and ST were equivalent (sample size: 1894; AT: 12.8% vs ST: 13.6%; OR 1.16; 95% CI  $0.59-2.28; P = 0.66; I^2 = 57\%$ ). Subgroup analyses of the outcome revealed no significant difference between adults (sample size: 1598; AT: 14.0% vs ST: 14.5%; OR 1.32; 95% CI 0.53–3.28; P = 0.55;  $I^2$ = 74%) and children (sample size: 296; AT: 7.1% vs ST: 8.7%; OR 0.86; 95% CI 0.31–2.36; P = 0.77;  $I^2 = 0\%$ ; Test for subgroup differences: P = 0.54;  $I^2 = 0\%$ ). In the same way, subgroup analysis of the outcome revealed no significant difference between RCTs (Sample size: 1179; AT: 16.9% vs ST: 15.3%; OR 1.77; 95% CI 0.58-5.35; P = 0.32;  $I^2 = 78\%$ ) and non-RCT studies (sample size: 715; AT: 6.8% vs ST: 10.6%; OR 0.64; 95% CI 0.32–1.29; P = 0.21;  $I^2 = 0\%$ ; test for subgroup differences: P = 0.13;  $I^2 = 56.6\%$ ) (Table 3) (Supp. Digit. Content. Fig. 4, http://links.lww.com/SLA/ B582).

Overall, the rate of wound infections (sample size: 1492; AT: 4.2% vs ST: 6.9%; OR 0.90; 95% CI 0.24–3.41; P = 0.87;  $I^2 = 68\%$ ), bowel obstruction (sample size: 1107; AT: 3.2% vs ST: 3.9%; OR 0.90; 95% CI 0.41–2.01; P = 0.80;  $I^2 = 0\%$ ), incisional hernia (sample size: 616; AT: 0% vs ST: 0.6; OR 1.33; 95% CI 0.15-11.81;  $P = 0.49; I^2 = 0\%$ ) and abscess formation (sample size: 1351; AT: 0.9% vs ST: 1.9; OR 1.08; 95% CI 0.41–2.80; P = 0.88;  $I^2 = 0\%$ ) were similar between the 2 groups (Supp. Digit. Content. Tab. 4, http://links.lww.com/SLA/B582), (Supp. Digit. Content. Fig. 5, http://links.lww.com/SLA/B582).

### **Total Costs**

The pooled analysis of primary costs included 7 stud-ies.<sup>9,10,26-28,34,37</sup>

Overall, AT resulted in significantly lower costs when compared to ST (sample size: 1147;  $2509.14 \pm 1621.5$  vs  $4898.57 \pm 3641.5$ ; SMD -3.65; 95% CI -5.36-1.93; P < 0.00001,  $I^2 = 98\%$ ). Two studies were included in the meta-analysis of all appendicitis-related care costs.<sup>10,27</sup> Results demonstrated significantly lower costs in the AT group (sample size: 152; AT: \$  $4074.50 \pm 204.3$  vs ST: \$  $5117 \pm 124.4$ ; SMD -0.69; 95% CI -1.02-0.35; P < 0.0001,  $I^2 = 43\%$ ) (Supp. Digit. Content. Tab. 3, http://links.lww.com/SLA/B582), (Supp. Digit. Content. Fig. 6, http://links.lww.com/SLA/B582).

## Length of Primary Hospital Stay

The pooled analysis of length of primary hospital stay included 13 studies.<sup>6–8,10,24–27,30,31,33,36,37</sup>

Overall, AT and ST showed an equivalent length of primary hospital stay (sample size: 3077; Days  $2.9 \pm 1.3$  vs Days  $3.3 \pm 1.7$ ; SMD -0.55; 95% CI -1.49-0.39; P = 0.25;  $I^2 = 99\%$ ). Subgroup analyses of the outcome revealed no significant difference between

© 2019 Wolters Kluwer Health, Inc. All rights reserved.

www.annalsofsurgery.com | 7

l

									Public Partic
(.)	Study or Subgroup	Antibio Events		Appende Events		Weight	Odds Ratio	Vear	Odds Ratio M-H, Random, 95% Cl
A	Study or Subgroup 1.11.1 Adults	Events	TOLAI	Events	TOLA	weight	M-H, Random, 95% CI	rear	M-H, Kandolin, 95% CI
$\square$	Eriksson S. 1995	12	20	18	20	3.7%	0 21 /0 04 1 161	1005	
		13 93	128	18	124	7.3%	0.21 [0.04, 1.16]		
	Styrud J. 2006 Hansson J. 2009	57	119	143	250	7.9%	0.42 [0.22, 0.80] 0.69 [0.44, 1.07]		
	Turhan AN. 2009	82	107	175	183	6.5%	0.15 [0.06, 0.35]		
	Vons C. 2011	63	119	114	120	6.3%	0.06 [0.02, 0.15]		
	Park HC. 2014	95	119	136	159	7.3%	0.67 [0.36, 1.26]		
	Salminen P. 2015	180	257	209	273	8.1%	0.72 [0.49, 1.05]		
	Poillucci G. 2017	87	162	159	184	7.7%	0.18 [0.11, 0.31]		
	Talan DA. 2017	13	16	12	14	3.2%	0.72 [0.10, 5.09]		
	Allievi N. 2017	232	284	89	109	7.5%	1.00 [0.57, 1.77]		1 <u>1</u>
	Subtotal (95% CI)		1331		1436	65.4%	0.37 [0.22, 0.63]		•
	Total events	915		1162					
	Heterogeneity: Tau <sup>2</sup> =				9 ( $P < 0$ .	00001);	$l^2 = 84\%$		
	Test for overall effect:	Z = 3.66	(P = 0)	.0003)					
	1.11.2 Children								
	Armstrong J. 2014	7	12	10	12	3.3%	0.28 [0.04, 1.88]		
	Minneci PC. 2015	28	37	56	65	5.8%	0.50 [0.18, 1.40]		
	Svensson JF. 2015	18	24	26	26	1.8%	0.05 [0.00, 1.01]		
	Hartwich J. 2016	17	24	50 9	50 9	1.8%	0.02 [0.00, 0.43]		
	Mahida JB. 2016 Tanaka Y. 2016	2 55	5 78	84		1.5% 4.3%	0.04 [0.00, 0.99]		
	Lee SL. 2017	17	51	25	86 32	4.5%	0.06 [0.01, 0.25] 0.14 [0.05, 0.39]		
	Mudri M. 2017	17	26	23	26	5.0%	0.45 [0.13, 1.60]		
	Gorter RR. 2017	9	25	8	19	5.2%	0.77 [0.23, 2.63]		
	Subtotal (95% CI)		282	-	325	34.6%	0.21 [0.10, 0.44]		•
	Total events	170		289					
	Heterogeneity: Tau <sup>2</sup> =	0.61; Ch	$i^2 = 16$	.38, df =	8 (P = 0.)	$(04); I^2 =$	51%		
	Test for overall effect:	Z = 4.09	(P < 0	.0001)					
	Total (95% CI)		1613		1761	100.0%	0.30 [0.20, 0.47]		
	Total events	1085	1013	1451	1/01	100.0%	0.30 [0.20, 0.47]		•
	Heterogeneity: Tau <sup>2</sup> =		$i^2 - 70$		18 (P < 0	00001	1 <sup>2</sup> - 77%		
	Test for overall effect:				10 (1 < 0		,1 = 77%		0.01 0.1 1 10 100
	Test for subgroup diff				1 (P = 0)	$(21) I^2 =$	35.5%		Favours [Antibiotics] Favours [Appendectomy]
	restror subgroup uni	cremers. c			- (1 - 0.		55.570		
		Antibio	tice	Appende	ctomy		Odds Ratio		Odds Ratio
$\frown$	Study or Subgroup	Events				Weight	M-H, Random, 95% CI	Year	
B	1.12.1 RCTs								
	Eriksson S. 1995	13	20	18	20	3.7%	0.21 [0.04, 1.16]	1995	·
	Styrud J. 2006	93	128	107	124	7.3%	0.42 [0.22, 0.80]		
	Hansson J. 2009	57	119	143	250	7.9%	0.69 [0.44, 1.07]		
	Turhan AN. 2009	82	107	175	183	6.5%	0.15 [0.06, 0.35]		
	Vons C. 2011	63	119	114	120	6.3%	0.06 [0.02, 0.15]	2011	
	Salminen P. 2015	180	257	209	273	8.1%	0.72 [0.49, 1.05]	2015	
	Svensson JF. 2015	18	24	26	26	1.8%	0.05 [0.00, 1.01]	2015	•
	Talan DA. 2017	13	16	12	14	3.2%	0.72 [0.10, 5.09]	2017	
	Subtotal (95% CI)		790		1010	44.7%	0.30 [0.15, 0.58]		•
	Total events	519		804					
	Heterogeneity: Tau <sup>2</sup> =				7 (P < 0.1)	00001);	r = 82%		
	Test for overall effect:	Z = 3.52	(P = 0)	.0004)					
	1.12.2 n-RCTs								
	Park HC. 2014	95	119	136	159	7.3%	0.67 [0.36, 1.26]	2014	
	Armstrong J. 2014	7	12	10	12	3.3%	0.28 [0.04, 1.88]		
	Minneci PC. 2015	28	37	56	65	5.8%	0.50 [0.18, 1.40]		




FIGURE 2. Meta-analysis of complication-free treatment success. Subgroup analyses: adults versus children [A], and RCTs versus n-RCTS [B].

8 | www.annalsofsurgery.com

© 2019 Wolters Kluwer Health, Inc. All rights reserved.

$\frown$		Antibio		Appende			Odds Ratio		Odds Ratio
A	Study or Subgroup 1.13.1 Adults	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
$\square$	Eriksson S. 1995	13	20	20	20	3.2%	0.04 [0.00, 0.83]	1995	· · · · · · · · · · · · · · · · · · ·
	Styrud J. 2006	97	128	120	124	7.2%	0.10 [0.04, 0.31]	2006	· · · · · ·
	Hansson J. 2009	93	119	223	250	8.3%	0.43 [0.24, 0.78]		
	Turhan AN. 2009	87	107	183	183	3.4%	0.01 [0.00, 0.19]		•
	Vons C. 2011	75	119	117	120	6.9%	0.04 [0.01, 0.15]		
	Park HC. 2014 Salminen P. 2015	96 186	119 257	152 254	159 273	7.7%	0.19 [0.08, 0.47] 0.20 [0.11, 0.34]		
	Talan DA. 2017	14	16	14	14	3.0%	0.20 [0.01, 4.54]		· · · · · · · · · · · · · · · · · · ·
	Allievi N. 2017	232	284	78	109	8.5%	1.77 [1.06, 2.96]		
	Poillucci G. 2017	87	162	159	184	8.5%	0.18 [0.11, 0.31]		<u> </u>
	Subtotal (95% CI)		1331		1436	65.0%	0.18 [0.08, 0.41]		•
	Total events	980		1320					
	Heterogeneity: Tau <sup>2</sup> =				9 (P < 0.0)	00001);	$^{2} = 88\%$		
	Test for overall effect:	Z = 4.09	(P < 0	.0001)					
	1.13.2 Children								
	Armstrong J. 2014	8	12	12	12	3.1%	0.08 [0.00, 1.59]	2014	· · · · · · · · · · · · · · · · · · ·
	Minneci PC. 2015	28	37	61	65	6.7%	0.20 [0.06, 0.72]		·
	Svensson JF. 2015	18	24	26	26	3.2%	0.05 [0.00, 1.01]	2015	← →
	Hartwich J. 2016	17	24	50	50	3.3%	0.02 [0.00, 0.43]	2016	<u>←                                    </u>
	Mahida JB. 2016	2	5	9	9	2.8%	0.04 [0.00, 0.99]		
	Tanaka Y. 2016	55	78	86	86	3.4%	0.01 [0.00, 0.23]		
	Lee SL. 2017	26	51	31	32	4.8%	0.03 [0.00, 0.26]		
	Mudri M. 2017 Gorter RR. 2017	17 21	26 25	25 19	26 19	4.6%	0.08 [0.01, 0.65] 0.12 [0.01, 2.42]		
	Subtotal (95% CI)	21	282	19	325	35.0%	0.08 [0.04, 0.16]	2017	-
	Total events	192	1000	319					
	Heterogeneity: Tau <sup>2</sup> =		i <sup>2</sup> = 5.8		(P = 0.66)	6); $I^2 = 0$	%		
	Test for overall effect:								
	Total (95% CI)		1613		1761	100.0%	0.12 [0.06, 0.24]		
	Total events	1172	1015	1639	1.01	100.070	0.12 [0.00, 0.24]		-
	Heterogeneity: Tau <sup>2</sup> =		$i^2 = 95$		18 (P < 0	.00001);	$l^2 = 81\%$		har de la characteria
	Test for overall effect:								0.01 0.1 1 10 100 Favours [Antibiotics] Favours [Appendectomy]
	Test for subgroup diff	erences: (	$Chi^2 = 2$	2.33, df =	1 (P = 0.	13), $ ^2 =$	57.0%		Tavours (Antibiotics) Tavours (Appendectority)
	Study or Subaroup	Antibi Events		Appende Events		Weight	Odds Ratio M-H. Random. 95% CI	Year	Odds Ratio M-H. Random, 95% Cl
В	Study or Subgroup 1.14.1 RCTs		otics Total			Weight	Odds Ratio M-H, Random, 95% CI	Year	Odds Ratio M-H, Random, 95% Cl
В	1.14.1 RCTs Eriksson S. 1995	Events	Total 20	Events 20	Total 20	3.2%			M-H, Random, 95% Cl
В	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006	Events 13 97	<b>Total</b> 20 128	20 120	<b>Total</b> 20 124	3.2% 7.2%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31]	1995 2006	M-H, Random, 95% Cl
В	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009	Events 13 97 93	<b>Total</b> 20 128 119	20 120 223	<b>Total</b> 20 124 250	3.2% 7.2% 8.3%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78]	1995 2006 2009	
В	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009	Events 13 97 93 87	<b>Total</b> 20 128 119 107	20 120 223 183	Total 20 124 250 183	3.2% 7.2% 8.3% 3.4%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19]	1995 2006 2009 2009	
В	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011	Events 13 97 93 87 75	Total 20 128 119 107 119	20 120 223 183 117	Total 20 124 250 183 120	3.2% 7.2% 8.3% 3.4% 6.9%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15]	1995 2006 2009 2009 2011	
В	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009	Events 13 97 93 87	Total 20 128 119 107 119 257	20 120 223 183 117 254	Total 20 124 250 183	3.2% 7.2% 8.3% 3.4%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 (0.01, 0.15] 0.20 [0.11, 0.34]	1995 2006 2009 2009 2011 2015	M-H, Random, 95% Cl
В	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015	Events 13 97 93 87 75 186	Total 20 128 119 107 119 257 24	20 120 223 183 117 254 26	Total 20 124 250 183 120 273	3.2% 7.2% 8.3% 3.4% 6.9% 8.4%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15]	1995 2006 2009 2009 2011 2015 2015	M-H, Random, 95% Cl
B	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Svensson JF. 2015 Talan DA. 2017 Subtotal (95% CI)	Events 13 97 93 87 75 186 18 14	Total 20 128 119 107 119 257 24 16 <b>790</b>	20 120 223 183 117 254 26 14	Total 20 124 250 183 120 273 26	3.2% 7.2% 8.3% 3.4% 6.9% 8.4% 3.2%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.05 [0.00, 1.01]	1995 2006 2009 2009 2011 2015 2015	M-H, Random, 95% Cl
B	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Svensson JF. 2015 Talan DA. 2017 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup>	Events 13 97 93 87 75 186 18 14 583 = 0.66; C	Total 20 128 119 107 119 257 24 16 <b>790</b> hi <sup>2</sup> = 21	20 120 223 183 117 254 26 14 957 1.53, df =	Total 20 124 250 183 120 273 26 14 1010	3.2% 7.2% 8.3% 3.4% 6.9% 8.4% 3.2% 3.0% <b>43.7%</b>	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.05 [0.00, 1.01] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26]	1995 2006 2009 2009 2011 2015 2015	M-H, Random, 95% Cl
B	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Svensson JF. 2015 Talan DA. 2017 <b>Subtotal (95% CI)</b> Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect	Events 13 97 93 87 75 186 18 14 583 = 0.66; C	Total 20 128 119 107 119 257 24 16 <b>790</b> hi <sup>2</sup> = 21	20 120 223 183 117 254 26 14 957 1.53, df =	Total 20 124 250 183 120 273 26 14 1010	3.2% 7.2% 8.3% 3.4% 6.9% 8.4% 3.2% 3.0% <b>43.7%</b>	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.05 [0.00, 1.01] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26]	1995 2006 2009 2009 2011 2015 2015	M-H, Random, 95% Cl
В	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Talan DA. 2017 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect 1.14.2 n-RCTs	Events 13 97 93 87 75 186 18 14 583 = 0.66; C t: Z = 5.2	Total 20 128 119 107 119 257 24 16 <b>790</b> hi <sup>2</sup> = 21 5 (P < 0	Events           20           120           223           183           117           254           26           14           957           1.53, df =           0.00001)	Total 20 124 250 183 120 273 26 14 1010 7 (P = 0.	3.2% 7.2% 8.3% 3.4% 6.9% 8.4% 3.2% 3.0% <b>43.7%</b> 003); l <sup>2</sup> =	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.05 [0.00, 1.01] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26] = 67%	1995 2006 2009 2011 2015 2015 2017	M-H, Random, 95% Cl
В	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Svensson JF. 2015 Talan DA. 2017 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect 1.14.2 n-RCTs Park HC. 2014	Events 13 97 93 87 75 186 18 14 583 = 0.66; C t: Z = 5.2 96	Total 20 128 119 107 107 257 24 16 <b>790</b> $hi^2 = 21$ 5 (P < 0 119	Events           20           120           223           183           117           254           26           14           957           1.53, df =           0.00001)           152	Total 20 124 250 183 120 273 26 14 1010 7 (P = 0. 159	3.2% 7.2% 8.3% 3.4% 6.9% 8.4% 3.2% 3.0% <b>43.7%</b> 003); l <sup>2</sup> =	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.50 [0.00, 1.01] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26] = 67%	1995 2006 2009 2011 2015 2015 2017 2017	M-H, Random, 95% Cl
B	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Svensson JF. 2015 Talan DA. 2015 <b>Subtotal (95% CI)</b> Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect 1.14.2 n-RCTs Park HC. 2014 Armstrong J. 2014	Events 13 97 93 87 75 186 18 14 583 = 0.66; C t: Z = 5.2 96 8	Total 20 128 119 107 119 257 24 16 <b>790</b> $hi^2 = 21$ 5 (P < 0 119 12	Events           20           120           223           183           117           254           26           14           957           1.53, df =           0.00001)           152           12	Total 20 124 250 183 120 273 26 14 1010 7 (P = 0. 159 12	3.2% 7.2% 8.3% 3.4% 6.9% 8.4% 3.2% 3.0% <b>43.7%</b> 003); I <sup>2</sup> = 7.7% 3.1%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.05 [0.00, 1.01] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26] = 67%	1995 2006 2009 2011 2015 2015 2017 2017 2014 2014	M-H, Random, 95% Cl
В	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect 1.14.2 n-RCTs Park HC. 2014 Armstrong J. 2014 Minneci PC. 2015	Events 13 97 93 87 75 186 18 14 583 = 0.66; C t: Z = 5.2 96 8 28	Total 20 128 119 257 24 16 790 $hi^2 = 21$ 5 (P < 0 119 237	20 120 223 183 117 254 26 14 957 1.53, df = 0.00001) 152 12 61	Total 20 124 250 183 120 273 266 14 1010 7 (P = 0. 159 12 65	3.2% 7.2% 8.3% 3.4% 6.9% 8.4% 3.2% 3.0% <b>43.7%</b> 0003); l <sup>2</sup> = 7.7% 3.1% 6.7%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.05 [0.00, 1.01] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26] = 67% 0.19 [0.08, 0.47] 0.08 [0.00, 1.59] 0.20 [0.06, 0.72]	1995 2006 2009 2011 2015 2015 2017 2017 2014 2014 2014 2014	M-H, Random, 95% Cl
В	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Talan DA. 2017 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect 1.14.2 n-RCTs Park HC. 2014 Armstrong J. 2014 Minneci PC. 2015 Mahida JB. 2016	Events 13 97 93 87 75 1866 18 14 583 = 0.66; C t: Z = 5.2 96 8 28 28 28 28 28 28 28 28 28	Total 20 128 119 257 24 16 790 $hi^2 = 21$ 5 (P < 0 119 237 5	20 120 223 183 117 254 26 14 957 1.53, df = 0.00001) 152 12 61 9	Total 20 124 250 183 120 273 26 14 1010 7 (P = 0. 159 12 65 9	3.2% 7.2% 8.3% 6.9% 8.4% 3.0% 43.7% 003); l <sup>2</sup> = 7.7% 3.1% 6.7% 2.8%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.05 [0.00, 1.01] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26] = 67% 0.19 [0.08, 0.47] 0.08 [0.00, 1.59] 0.20 [0.06, 0.72] 0.04 [0.00, 0.99]	1995 2006 2009 2011 2015 2015 2017 2017 2014 2014 2014 2015 2016	M-H, Random, 95% CI
B	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect 1.14.2 n-RCTs Park HC. 2014 Armstrong J. 2014 Minneci PC. 2015	Events 13 97 93 87 75 186 18 14 583 = 0.66; C t: Z = 5.2 96 8 28	Total 20 128 107 119 257 24 16 <b>790</b> $hi^2 = 21$ 5 (P < 0 119 12 37 5 78	20 120 223 183 117 254 26 14 957 1.53, df = 0.00001) 152 12 61 9 9 86	Total 20 124 250 183 120 273 266 14 1010 7 (P = 0. 159 12 65	3.2% 7.2% 8.3% 3.4% 6.9% 8.4% 3.2% 3.0% <b>43.7%</b> 0003); l <sup>2</sup> = 7.7% 3.1% 6.7%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.05 [0.00, 1.01] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26] = 67% 0.19 [0.08, 0.47] 0.08 [0.00, 1.59] 0.20 [0.06, 0.72]	1995 2006 2009 2011 2015 2015 2017 2017 2014 2014 2014 2016 2016	M-H, Random, 95% CI
B	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Svensson JF. 2015 Talan DA. 2017 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Total events Heterogeneity: 2015 1.14.2 n-RCTs Park HC. 2014 Minida JB. 2016 Tanaka Y. 2016	Events 13 97 93 87 755 186 18 14 583 = 0.66; C t: Z = 5.2 96 8 28 28 25 55	Total 20 128 119 107 119 257 24 16 <b>790</b> hi <sup>2</sup> = 21 5 (P < 0 119 12 37 5 78 24 24 24 24 24 24 24 24 24 25 24 24 24 24 24 24 24 24 24 24	20 120 223 183 117 254 26 14 957 1.53, df = 0.00001) 152 12 61 9 86 650	Total 20 124 250 183 120 273 26 14 1010 7 (P = 0. 159 12 65 9 86	3.2% 7.2% 8.3% 3.4% 6.9% 8.4% 3.2% 3.0% <b>43.7%</b> 0003); l <sup>2</sup> = 7.7% 3.1% 6.7% 2.8% 3.4%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.05 [0.00, 1.01] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26] = 67% 0.19 [0.08, 0.47] 0.08 [0.00, 1.59] 0.20 [0.06, 0.72] 0.04 [0.00, 0.99] 0.01 [0.00, 0.33]	1995 2006 2009 2011 2015 2015 2015 2017 2014 2014 2014 2016 2016 2016	M-H, Random, 95% CI
B	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Svensson JF. 2015 Talan DA. 2017 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect 1.14.2 n-RCTs Park HC. 2014 Armstrong J. 2014 Minneci PC. 2015 Mahida JB. 2016 Tanaka Y. 2016 Hartwich J. 2016 Allievi N. 2017 Poillucci G. 2017	Events 13 97 93 87 75 186 18 14 583 = 0.66; C t: Z = 5.2 96 8 28 25 17 232 87 75 186 18 14 583 28 28 28 28 28 28 28 28 28 28	Total 20 128 119 107 119 257 24 16 <b>790</b> hi <sup>2</sup> = 21 5 (P < 0 119 12 37 5 78 24 24 16 <b>790</b> 128 19 19 257 24 16 <b>790</b> 128 19 19 257 24 16 <b>790</b> 128 <b>790</b> 128 <b>790</b> 128 <b>790</b> 128 <b>790</b> 128 <b>790</b> 128 <b>790</b> 128 <b>790</b> 128 <b>790</b> 128 <b>790</b> 128 <b>790</b> 128 <b>790</b> 128 <b>790</b> 128 <b>790</b> 128 <b>790</b> 129 <b>257</b> <b>7</b> 8 <b>24</b> <b>15</b> <b>15</b> <b>16</b> <b>17</b> 9 <b>17</b> 9	20 120 223 183 117 254 26 14 957 1.53, df = 0.00001) 152 12 61 9 86 50 78 86 50 78 81 59	Total 20 124 250 183 120 273 26 14 1010 7 (P = 0. 159 12 65 9 86 50 109 184	3.2% 7.2% 8.3% 3.4% 6.9% 8.4% 3.2% 3.0% <b>43.7%</b> 003); 1 <sup>2</sup> = 7.7% 3.1% 6.7% 2.8% 3.4% 3.3% 8.5%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.05 [0.00, 1.01] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26] = 67% 0.19 [0.08, 0.47] 0.08 [0.00, 1.59] 0.20 [0.06, 0.72] 0.04 [0.00, 0.99] 0.01 [0.00, 0.23] 0.02 [0.00, 0.43] 1.77 [1.06, 2.96] 0.18 [0.11, 0.31]	1995 2006 2009 2011 2015 2015 2017 2017 2014 2014 2014 2016 2016 2016 2017 2017	M-H, Random, 95% CI
B	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Subtoal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect 1.14.2 n-RCTs Park HC. 2014 Armstrong J. 2014 Minneci PC. 2015 Mahida JB. 2016 Hartwich J. 2016 Allievi N. 2017 Poillucci G. 2017 Lee SL. 2017	Events 13 97 93 87 75 186 18 14 583 = 0.66; C t: Z = 5.2 966 8 28 28 28 55 17 232 8 5 17 232 8 5 17 26	$\begin{array}{c} \textbf{Total} \\ 200 \\ 128 \\ 119 \\ 107 \\ 119 \\ 257 \\ 244 \\ 166 \\ \textbf{790} \\ \textbf{h}^2 = 21 \\ 55 \\ (P < C \\ \textbf{119} \\ 12 \\ 377 \\ \textbf{5} \\ \textbf{78} \\ 244 \\ 162 \\ \textbf{51} \\ \textbf{164} \\ \textbf{162} \\ \textbf{51} \\ \textbf{164} \\ \textbf{162} \\ \textbf{51} \\ \textbf{164} \\ \textbf{166} \\ \textbf{166} \\ \textbf{51} \\ \textbf{166} \\ \textbf{166} \\ \textbf{166} \\ \textbf{166} \\ \textbf{51} \\ \textbf{166} \\ $	20 120 223 183 117 254 26 14 957 1.53, df = 0.00001) 152 12 61 9 86 50 78 50 78 31	Total 20 124 250 183 120 273 26 14 1010 7 (P = 0. 159 12 65 9 86 50 109 184 32	3.2% 7.2% 8.3% 3.4% 6.9% 8.4% 3.2% 3.0% <b>43.7%</b> 003); l <sup>2</sup> = 7.7% 3.1% 6.7% 2.8% 3.3% 8.5% 8.5% 8.5%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26] = 67% 0.19 [0.08, 0.47] 0.08 [0.00, 1.59] 0.20 [0.06, 0.72] 0.04 [0.00, 0.33] 0.02 [0.00, 0.43] 1.77 [1.06, 2.96] 0.18 [0.11, 0.31] 0.03 [0.00, 0.26]	1995 2006 2009 2011 2015 2015 2015 2017 2017 2014 2014 2016 2016 2016 2016 2017 2017	M-H, Random, 95% CI
B	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Talan DA. 2017 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> : Test for overall effect 1.14.2 n-RCTs Park HC. 2014 Armstrong J. 2014 Minneci PC. 2015 Mahida JB. 2016 Tanaka Y. 2016 Hartwich J. 2017 Poillucci G. 2017 Lee SL. 2017 Mudri M. 2017	Events 13 97 93 87 75 186 18 14 583 = 0.66; C t: Z = 5.2 96 8 288 28 28 7 75 186 18 14 583 28 28 28 28 28 28 28 28 28 28	Total           200         128           119         107           107         119           257         24           16         6           790         790           119         12           37         5           78         24           284         162           51         24           12         37           5         78           24         284           162         51	20 120 223 183 117 254 26 14 957 1.53, df = 0.00001) 152 12 61 9 86 50 0 78 159 31 25	Total 20 124 250 183 120 273 26 14 1010 7 (P = 0. 159 12 65 9 86 50 109 184 32 26 14 109 12 25 12 25 12 26 12 12 26 12 27 26 12 27 26 12 27 26 12 27 26 12 27 26 12 27 26 12 27 26 14 27 26 14 27 26 14 27 26 14 27 26 14 27 26 14 27 26 14 27 26 14 27 26 14 27 26 14 27 26 14 27 26 14 27 26 14 27 26 14 27 26 12 27 26 12 27 26 12 27 27 26 12 27 27 27 27 27 27 27 27 27 2	3.2% 7.2% 8.3% 3.4% 6.9% 8.4% 3.2% 3.0% <b>43.7%</b> 003); I <sup>2</sup> = 7.7% 3.1% 6.7% 2.8% 3.4% 3.3% 8.5% 4.6%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.05 [0.00, 1.01] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26] = 67% 0.19 [0.08, 0.47] 0.08 [0.00, 1.59] 0.20 (0.06, 0.72] 0.04 [0.00, 0.39] 0.01 [0.00, 0.43] 0.77 [1.06, 2.96] 0.18 [0.11, 0.31] 0.03 [0.00, 0.65]	1995 2006 2009 2011 2015 2017 2017 2014 2014 2014 2016 2016 2016 2016 2017 2017	M-H, Random, 95% CI
B	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Svensson JF. 2015 Talan DA. 2017 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> : Test for overall effect 1.14.2 n-RCTs Park HC. 2014 Armstrong J. 2014 Minneci PC. 2015 Mahida JB. 2016 Tanaka Y. 2016 Hartwich J. 2016 Allievi N. 2017 Desl. 2017 Lee SL. 2017 Mudri M. 2017	Events 13 97 93 87 75 186 18 14 583 = 0.66; C t: Z = 5.2 966 8 28 28 28 55 17 232 8 5 17 232 8 5 17 26	Total           200         128           119         107           107         119           257         24           16         6           790         790           119         12           37         5           78         24           284         162           51         24           12         37           5         78           24         284           162         51	20 120 223 183 117 254 26 14 957 1.53, df = 0.00001) 152 12 61 9 86 50 78 86 50 78 81 59 31 25 19	Total 20 124 250 183 120 273 26 14 1010 7 (P = 0. 159 12 65 9 86 50 109 184 32	3.2% 7.2% 8.3% 3.4% 6.9% 3.2% 3.2% 43.7% 003); 1 <sup>2</sup> = 7.7% 3.1% 6.7% 2.8% 3.4% 3.3% 8.5% 4.8% 4.6% 3.2%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.05 [0.00, 1.01] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26] = 67% 0.19 [0.08, 0.47] 0.08 [0.00, 1.59] 0.20 [0.06 0.72] 0.04 [0.00, 0.23] 0.02 [0.00, 0.43] 1.77 [1.06, 2.96] 0.18 [0.11, 0.31] 0.3 [0.00, 0.26] 0.08 [0.01, 0.65] 0.12 [0.01, 2.42]	1995 2006 2009 2011 2015 2017 2017 2014 2014 2014 2016 2016 2016 2016 2017 2017	M-H, Random, 95% CI
B	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Talan DA. 2017 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> : Test for overall effect 1.14.2 n-RCTs Park HC. 2014 Armstrong J. 2014 Minneci PC. 2015 Mahida JB. 2016 Tanaka Y. 2016 Hartwich J. 2017 Poillucci G. 2017 Lee SL. 2017 Mudri M. 2017	Events 13 97 93 87 75 186 18 14 583 = 0.66; C t: Z = 5.2 96 8 288 28 28 7 75 186 18 14 583 28 28 28 28 28 28 28 28 28 28	Total           20           20           128           119           107           24           6790           hi² = 21           55           78           24           128           119           257           780           78           24           12           37           5           78           24           26           12           37           5           823	20 120 223 183 117 254 26 14 957 1.53, df = 0.00001) 152 12 61 9 86 50 78 86 50 78 81 59 31 25 19	Total 20 124 250 183 120 273 26 14 1010 7 (P = 0. 159 12 65 9 86 50 109 184 32 26 14 273 26 14 273 26 14 273 26 14 273 26 14 273 26 14 20 273 26 14 20 273 26 14 20 273 26 14 20 273 26 14 20 273 26 14 20 273 26 14 20 273 26 14 20 273 26 14 20 273 26 14 20 273 26 14 20 273 26 14 20 273 26 14 20 273 26 14 20 273 26 273 26 273 26 273 26 273 26 273 26 273 26 273 26 273 26 273 26 273 26 273 26 273 26 273 26 273 27 26 27 26 27 27 26 27 27 26 29 86 50 109 184 32 26 26 26 27 27 26 26 29 26 20 27 26 26 20 27 20 26 20 20 20 20 20 20 20 20 20 20	3.2% 7.2% 8.3% 3.4% 6.9% 8.4% 3.2% 3.0% <b>43.7%</b> 003); I <sup>2</sup> = 7.7% 3.1% 6.7% 2.8% 3.4% 3.3% 8.5% 4.6%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.05 [0.00, 1.01] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26] = 67% 0.19 [0.08, 0.47] 0.08 [0.00, 1.59] 0.20 (0.06, 0.72] 0.04 [0.00, 0.39] 0.01 [0.00, 0.43] 0.77 [1.06, 2.96] 0.18 [0.11, 0.31] 0.03 [0.00, 0.65]	1995 2006 2009 2011 2015 2017 2017 2014 2014 2014 2016 2016 2016 2016 2017 2017	M-H, Random, 95% CI
B	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Svensson JF. 2015 Talan DA. 2017 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect 1.14.2 n-RCTs Park HC. 2014 Armstrong J. 2014 Minneci PC. 2015 Mahida JB. 2016 Hartwich J. 2016 Allievi N. 2017 Poillucci G. 2017 Lee SL. 2017 Mudri M. 2017 Subtotal (95% CI)	Events 13 97 93 87 75 186 18 14 583 = 0.66; C t: Z = 5.2 96 8 28 28 28 28 25 17 232 87 26 17 23 28 7 26 17 23 87 28 28 28 28 28 28 28 28 28 28	Total           20           128           119           107           119           257           24           6           790           hi² = 212           119           12           37           78           244           162           25           823           823           hi² = 67	20 120 223 183 117 254 26 14 957 1.53, df = 9 86 50 78 86 50 78 81 59 31 25 19 86 27,23, df =	Total 20 124 250 133 120 273 26 14 1010 7 (P = 0. 159 12 65 5 9 86 50 109 184 322 6 5 9 86 50 109 184 326 199 125 125 125 125 125 125 125 125	3.2% 7.2% 8.3% 3.4% 6.9% 8.4% 3.2% 3.0% 43.7% 003); I <sup>2</sup> = 7.7% 6.7% 2.8% 3.1% 6.7% 2.8% 3.3% 8.5% 8.5% 4.8% 4.6% 3.2% 56.3%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.50 [0.00, 1.01] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26] = 67% 0.19 [0.08, 0.47] 0.08 [0.00, 1.59] 0.20 [0.06, 0.72] 0.04 [0.00, 0.99] 0.10 [0.00, 0.33] 0.02 [0.00, 0.43] 1.77 [1.06, 2.96] 0.18 [0.11, 0.31] 0.03 [0.00, 0.26] 0.08 [0.01, 0.65] 0.12 [0.04, 0.35] 0.12 [0.04, 0.35]	1995 2006 2009 2011 2015 2017 2017 2014 2014 2014 2016 2016 2016 2016 2017 2017	M-H, Random, 95% CI
B	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Svensson JF. 2015 Talan DA. 2017 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect 1.14.2 n-RCTs Park HC. 2014 Armstrong J. 2014 Minneci PC. 2015 Mahida JB. 2016 Tanaka Y. 2016 Hartwich J. 2016 Allievi N. 2017 Poillucci G. 2017 Lee SL. 2017 Subtotal (95% CI) Total events	Events 13 97 93 87 75 186 18 14 583 = 0.66; C t: Z = 5.2 96 8 28 28 28 28 25 17 232 87 26 17 23 28 7 26 17 23 87 28 28 28 28 28 28 28 28 28 28	Total           20           128           119           107           119           257           24           6           790           hi² = 212           119           12           37           78           244           162           25           823           823           hi² = 67	20 120 223 183 117 254 26 14 9 957 1.53, df = 0.00001) 152 12 61 9 86 50 0 78 159 31 25 19 682 7.23, df = 0.0001)	Total 20 124 250 183 120 273 26 14 1010 7 (P = 0. 159 12 65 9 86 50 109 184 322 6 19 751 10 (P < 0)	3.2% 7.2% 8.3% 3.4% 6.9% 8.4% 3.2% 3.0% 43.7% 003); I <sup>2</sup> = 7.7% 6.7% 2.8% 3.1% 6.7% 2.8% 3.3% 8.5% 8.5% 4.8% 4.6% 3.2% 56.3%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.50 [0.00, 1.01] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26] = 67% 0.19 [0.08, 0.47] 0.08 [0.00, 1.59] 0.20 [0.06, 0.72] 0.04 [0.00, 0.99] 0.10 [0.00, 0.33] 0.02 [0.00, 0.43] 1.77 [1.06, 2.96] 0.18 [0.11, 0.31] 0.03 [0.00, 0.26] 0.08 [0.01, 0.65] 0.12 [0.04, 0.35] 0.12 [0.04, 0.35]	1995 2006 2009 2011 2015 2017 2017 2014 2014 2014 2016 2016 2016 2016 2017 2017	M-H, Random, 95% CI
B	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Svensson JF. 2015 Talan DA. 2017 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect 1.14.2 n-RCTs Park HC. 2014 Armstrong J. 2014 Minneci PC. 2015 Mahida JB. 2016 Hartwich J. 2016 Allievi N. 2017 Doilla ci G. 2017 Lee SL. 2017 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Total (95% CI) Total events	Events 13 97 93 87 75 186 14 583 0.66; Ct t Z = 5.2 96 8 28 25 17 26 17 26 17 21 589 = 1.99; Ct t Z = 3.9 1172	Total           20           20           128           119           107           24           6           790           hi² = 21           5 (P < C	20 120 223 183 117 254 26 14 957 1.53, df = 0.00001) 152 12 61 9 86 50 78 81 59 31 25 19 9 86 50 78 81 59 31 25 19 9 86 50 78 86 50 78 81 59 31 25 19 81 19 19 19 19 19 10 10 10 10 10 10 10 10 10 10 10 10 10	Total 20 124 250 183 120 273 26 14 1010 7 (P = 0. 159 12 65 9 86 50 109 184 32 26 19 12 10 10 12 10 10 10 10 10 10 10 10 10 10	3.2% 7.2% 8.3% 3.4% 6.9% 8.4% 3.2% 3.0% 43.7% 003); l <sup>2</sup> = 7.7% 3.1% 6.7% 2.8% 3.4% 3.3% 8.5% 8.5% 4.8% 4.6% 3.2% 56.3%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.05 [0.00, 1.01] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26] = 67% 0.19 [0.08, 0.47] 0.08 [0.00, 1.59] 0.20 [0.06, 0.72] 0.04 (0.00, 0.99] 0.01 [0.00, 0.23] 0.02 [0.00, 0.43] 1.77 [1.06, 2.96] 0.18 [0.11, 0.31] 0.03 [0.00, 0.26] 0.08 [0.11, 0.51] 0.03 [0.00, 0.26] 0.12 [0.04, 0.35] ; l <sup>2</sup> = 85% 0.12 [0.06, 0.24]	1995 2006 2009 2011 2015 2017 2017 2014 2014 2014 2016 2016 2016 2016 2017 2017	M-H, Random, 95% CI
B	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Subtoal (95%CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect 1.14.2 n-RCTs Park HC. 2014 Armstrong J. 2014 Minneci PC. 2015 Mahida JB. 2016 Hartwich J. 2016 Allievi N. 2017 Poillucci G. 2017 Ee SL. 2017 Mudri M. 2017 Gorter RR. 2017 Gorter RR. 2017 Gotter RR. 2017 Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Total (95%CI) Total events Heterogeneity: Tau <sup>2</sup>	Events 13 97 93 87 75 186 18 14 583 = 0.66; C t: Z = 5.2 96 8 28 28 28 27 25 17 232 87 26 17 232 87 26 17 232 87 26 17 26 28 28 28 28 28 28 28 28 28 28	Total           200           128           119           257           24           16           790           hh² = 212           37           55           78           244           162           377           5           78           244           284           162           253           84           26           253           86           1613           hh² = 95	20 120 223 183 117 254 26 14 957 1.53, df = 0.00001) 152 12 61 9 86 50 78 159 31 25 19 682 7.23, df = 0.00001) 1639 5.70, df =	Total 20 124 250 183 120 273 26 14 1010 7 (P = 0. 159 12 65 9 86 50 109 184 32 26 19 12 10 10 12 10 10 10 10 10 10 10 10 10 10	3.2% 7.2% 8.3% 3.4% 6.9% 8.4% 3.2% 3.0% 43.7% 003); l <sup>2</sup> = 7.7% 3.1% 6.7% 2.8% 3.4% 3.3% 8.5% 8.5% 4.8% 4.6% 3.2% 56.3%	M-H, Random, 95% CI 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.05 [0.00, 1.01] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26] = 67% 0.19 [0.08, 0.47] 0.08 [0.00, 1.59] 0.20 [0.06, 0.72] 0.04 (0.00, 0.99] 0.01 [0.00, 0.23] 0.02 [0.00, 0.43] 1.77 [1.06, 2.96] 0.18 [0.11, 0.31] 0.03 [0.00, 0.26] 0.08 [0.11, 0.51] 0.03 [0.00, 0.26] 0.12 [0.04, 0.35] ; l <sup>2</sup> = 85% 0.12 [0.06, 0.24]	1995 2006 2009 2011 2015 2017 2017 2014 2014 2014 2016 2016 2016 2016 2017 2017	M-H, Random, 95% CI
B	1.14.1 RCTs Eriksson S. 1995 Styrud J. 2006 Hansson J. 2009 Turhan AN. 2009 Vons C. 2011 Salminen P. 2015 Svensson JF. 2015 Talan DA. 2017 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect 1.14.2 n-RCTs Park HC. 2014 Armstrong J. 2014 Minneci PC. 2015 Mahida JB. 2016 Hartwich J. 2016 Allievi N. 2017 Doilla ci G. 2017 Lee SL. 2017 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Total (95% CI) Total events	Events 13 97 93 87 75 186 18 14 583 = 0.66; C t: Z = 5.2 96 8 28 28 28 28 28 28 28 28 28	Total           200           128           119           107           24           16           790           hi <sup>2</sup> = 212           55 (P < C	20 120 223 183 117 254 26 14 957 1.53, df = 0.00001) 152 12 61 9 86 50 78 86 50 78 159 31 25 19 682 7.23, df = 0.0001) 1639 5.70, df = 0.00001)	Total           20           124           250           183           120           273           26           14           1010           7 (P = 0.           159           12           65           9           86           10           26           19           751           10 (P < 0	3.2% 7.2% 8.3% 3.4% 6.9% 8.4% 3.2% 3.0% 43.7% 003); l <sup>2</sup> = 7.7% 3.1% 6.7% 2.8% 3.4% 3.3% 8.5% 4.6% 3.2% 56.3% 0.00001) 100.0%	M-H, Random, 95% Cl 0.04 [0.00, 0.83] 0.10 [0.04, 0.31] 0.43 [0.24, 0.78] 0.01 [0.00, 0.19] 0.04 [0.01, 0.15] 0.20 [0.11, 0.34] 0.50 [0.00, 1.01] 0.20 [0.01, 4.54] 0.12 [0.05, 0.26] = 67% 0.19 [0.08, 0.47] 0.08 [0.00, 1.59] 0.20 [0.06, 0.72] 0.04 [0.00, 0.39] 0.01 [0.00, 0.33] 0.02 [0.00, 0.43] 0.77 [1.06, 2.96] 0.18 [0.11, 0.31] 0.03 [0.00, 0.65] 0.12 [0.04, 0.35] 0.12 [0.04, 0.35] 0.12 [0.06, 0.24] ; l <sup>2</sup> = 81%	1995 2006 2009 2011 2015 2017 2017 2014 2014 2014 2016 2016 2016 2016 2017 2017	M-H, Random, 95% CI

FIGURE 3. Meta-analysis of treatment efficacy based on 1-year follow-up. Subgroup analyses: adults versus children [A], and RCTs versus n-RCTS [B].

© 2019 Wolters Kluwer Health, Inc. All rights reserved.

adults (sample size: 2737; SMD -0.20; 95% CI -1.34-0.93; P = 0.73;  $I^2 = 99\%$ ) and children (sample size: 340; SMD -1.40; 95% CI -3.71-0.92; P = 0.24;  $I^2 = 98\%$ ; test for subgroup differences: P = 0.36;  $I^2 = 0\%$ ).

In non-RCT studies (sample size: 1770; SMD -1.52; 95% CI -2.42-0.63; P = 0.0009;  $I^2 = 98\%$ ) AT resulted in a significantly shorter length of stay, whereas in RCTs (sample size: 1307; SMD 0.35; 95% CI -1.30-2.00; P = 0.68;  $I^2 = 99\%$ ) the difference was not statistically significant. Test for subgroup differences (P = 0.05;  $I^2 = 73.7\%$ ) indicated that there was no statistically significant subgroup effect, suggesting that the study design did not modify the effect of AT in comparison with ST (Supp. Digit. Content. Tab. 4, http://links.lww.com/SLA/B582).

Total length of stay per patient, duration of pain, length of sick leave, length of time off work, the total length of stay per patient were documented in 4 studies.<sup>31–34</sup> It did not differ significantly between AT and ST (sample size: 744; Days  $2.9 \pm 1.2$  vs Days  $3.8 \pm 1.3$ ; SMD -0.32; 95% CI -0.74-0.09; P = 0.12;  $I^2 = 81\%$ ).

Duration of pain was evaluated in 3 studies.<sup>8,32,37</sup> Results of the pooled analysis did not demonstrate any statistically significant difference between AT and ST (sample size: 691; Days  $3.2 \pm 1.7$  vs Days  $4.9 \pm 3.1$ ; SMD -1.62; 95% CI -3.61-0.38; P = 0.11;  $I^2 = 99\%$ ).

The length of sick leave was reported by 5 authors.<sup>6,7,27,32,37</sup> Overall, results of the pooled analysis did not differ significantly between AT and ST (sample size: 1336; Days  $8.4 \pm 6$  vs Days  $10 \pm 6$ ; SMD -0.57; 95% CI -4.24-3.10; P = 0.76;  $I^2 = 100\%$ ). In the same way, subgroup analyses of the outcome revealed no significant difference between adults (Sample size: 1151; SMD -0.61; 95% CI -5.10-6.31; P = 0.83;  $I^2 = 100\%$ ) and children (sample size: 185; SMD -2.33; 95% CI -5.76-1.09; P = 0.18;  $I^2 = 99\%$ ; Test for subgroup differences: P = 0.39;  $I^2 = 0\%$ ).

The length of time off work, documented in 3 studies,<sup>7,8,31</sup> did not show any statistically significant difference between AT and ST (sample size: 884; Days 7.9 ± 1.9 vs Days 11.7 ± 2.5; SMD -0.52; 95% CI -1.24-0.20; P = 0.15;  $I^2 = 96\%$ ) (Supp. Digit. Content. Tab. 4, http://links.lww.com/SLA/B582), (Supp. Digit. Content. Fig. 8, http://links.lww.com/SLA/B582).

# Quality of Life

Three studies provided data regarding quality of life.<sup>9,27,32</sup> However, due to the different scales used to assess the outcome, it was not possible to perform a pooled analysis. In the study by Talan et al, AT patients had higher physical SF-12v2 Health Survey scores than ST patients both at 2-weeks (median 54 vs 44) and at 1-month follow-up (median 56 vs 47).<sup>9</sup>

On the other hand, results of the mental SF-12v2 component showed higher values for patients who underwent ST both at 2 weeks (median 58 vs 55) and at 1 month follow-up (median 56 vs 55). In children, Minneci et al (95.7 vs 91.3) and Lee et al (100 vs 100) reported similar Pediatric Quality of Life scores between AT and ST groups at 1-year and at 1-month, respectively.<sup>27,32</sup>

#### DISCUSSION

This comprehensive systematic review and meta-analysis of 20 studies including over 3600 patients has demonstrated that antibiotic therapy as a primary nonoperative management strategy for uncomplicated appendicitis in both adults and children is associated with a treatment failure rate of 27.7% at 1 year follow-up, a lower complication-free treatment success rate compared to appendectomy (67.2% vs 82.3%, P < 0.0006) and a tendency toward a doubled (although not statistically significant) incidence of

complicated appendicitis at delayed surgery in the overall population (21.7% vs 12.8%, P = 0.07), especially in adults (21.8% vs 12.7%, P = 0.06). Nevertheless, there are some advantages to antibiotic therapy over appendectomy with lower rate of postintervention complications (7.1% vs 14.5%, P = 0.006) and reduced healthcare costs. All other outcomes that impact the patient experience, including complications following surgery, length of hospitalization, duration of pain, length of sick leave, and length of time off work, did not show any statistically significant difference between the 2 different treatment modalities.

Our results are in line with those reported by Sallinen et al in their recent meta-analysis. These authors found a similar incidence of recurrent appendicitis at 1 year (22.6%) compared with our results (19.2%) and concluded that the tradeoff between AT and ST (3% fewer major complications, 7% fewer minor complications, a mean of 4 days' shorter sick leave, and 92% fewer appendectomies in the first month) must be balanced against a 23% recurrence rate within 1 year of follow-up and slightly longer hospital stay.<sup>14</sup>

In accordance with the Affordable Care Act (ACA), patients need to be informed of the most recent clinical evidence regarding management of appendicitis, and engaged in sharing decision-making processes.<sup>38</sup> Despite this established principle, little is known about patients' attitudes and expectations when a diagnosis of appendicitis is made. In 2018, an anonymous Internet-based survey conducted by Hanson et al, asked survey respondents to choose a treatment between laparoscopic appendectomy, open appendectomy, and NOM with antibiotics in the eventuality they had uncomplicated appendicitis. Of the 1738 respondents, 85.8% chose laparoscopic appendectomy, and 9.4% antibiotics alone. This study provides a robust evidence base to support creation of decision aids that may help patients with uncomplicated appendicitis be better involved in decisions about their care.<sup>39</sup>

Unfortunately, we were not able to perform any type of metaanalysis for quality of life following NOM with antibiotics and appendectomy. Although in children equivalent Pediatric Quality of Life scores have been reported, it is interesting to note that results of the mental SF-12v2 component score demonstrated higher values for adult patients who underwent surgery than for those treated with NOM in the study by Talan et al. This finding adds to the debate on the current perceptions of the antibiotic-first strategy for uncomplicated appendicitis, possibly demonstrating anxiety about future episodes of abdominal pain in patients who did not receive definitive surgical treatment, and introducing an element of decisional regret.<sup>9</sup>

Few studies have focused on how to distinguish patients who might respond well to NOM with antibiotics from those who require appendectomy. Hansson et al, in their report on 581 patients published in 2014, found that patients with assumed uncomplicated appendicitis who fulfilled all criteria with CRP <60 g/L, WBC <12 × 10<sup>9</sup>/L and age <60 years had an 89% chance of recovery with antibiotics.<sup>40</sup> In another recent study, patients with a longer duration of symptoms prior to admission (> 24 h) were more likely to have successful NOM, probably because the lack of progression to complicated disease is associated with an indolent clinical evolution. Other independent predictors of success included lower temperature, imaging-confirmed uncomplicated appendicitis with lower modified Alvarado score (< 4), and smaller diameter of the appendix.<sup>41</sup>

The prospective trial by Mahida et al reported that the failure rate of NOM in children affected by uncomplicated appendicitis with appendicolith was high (60%) at a median follow-up of less than 5 months.<sup>29</sup> The presence of an appendicolith has been associated with high failure rates in the reports published by Tanaka et al (failure rate: 47%), Svensson et al (failure rate: 60%), and Lee et al, concluding that patients with evidence of appendicolith on imaging had an initial

10 | www.annalsofsurgery.com

© 2019 Wolters Kluwer Health, Inc. All rights reserved.

failure rate of NOM more than twice that of patients without an appendicolith.  $^{10,30,32}$ 

The theory hypothesizing that perforated appendicitis might be a different disease entity from uncomplicated appendicitis, rather than being the natural evolution of the disease, has some support in a recent meta-analysis demonstrating that delaying appendectomy for up to 24 hours after admission does not appear to be a risk factor for complicated appendicitis, postoperative morbidity, or surgical-site infection.<sup>42</sup>

In our meta-analysis, although the odds ratio for complicated appendicitis was doubled in adult patients undergoing surgery following failure of NOM with antibiotics, the difference did not reach statistical significance. In the subgroup analysis of pediatric patients, where all the participants underwent preliminary ultrasound or CT scan, the odds ratio was 1.17, demonstrating comparable risk of complicated appendicitis between AT and ST. With the caveat that some of the studies included in this met-analysis are derived from low quality scientific evidence, our pooled results indicate that a trial of antibiotic therapy does not lead to a statistically significant increased risk of developing diffuse peritonitis.

When analyzing patients who underwent surgery after failure of AT, similar rates of surgical complications were reported in the AT and ST groups (12.8% vs 13.6%), suggesting that the decision to delay appendectomy can be safely made without excess risk of developing postoperative complications as a result. In the same way, the systematic review by Gorter et al concluded that children with uncomplicated appendicitis who needed a delayed appendectomy for early failure, recurrent appendicitis, or interval appendectomy following NOM did not experience more surgical complications than those who underwent immediate appendectomy.<sup>43</sup>

The incidence of intraoperative finding of complicated appendicitis, however, may not be considered a reliable outcome of safety in the evaluation of NOM. Complicated appendicitis might already have been present in a percentage of patients at the time of randomization, and so, the question arises as to whether this could be related to a lack of accuracy in the diagnostic process, rather than a real progression of uncomplicated appendicitis on to perforation. Within RCTs that used CT scan to reach a precise diagnosis of uncomplicated appendicitis, the rate of perforated appendicitis varied from 18% in the surgery group in the study by Vons et al [*Vons*] to 1% in the trial by Salminen et al.<sup>6</sup> This suggests that even CT scan is not able to distinguish with absolute certainty uncomplicated from perforated forms of appendicitis, especially in the absence of clear findings of extraluminal air, increased wall thickness > 3 mm, and intraluminal fecalith.<sup>44</sup>

Based on the study published by Wu et al, NOM without interval appendectomy is the least costly and most effective treatment strategy for adult patients with uncomplicated appendicitis. Health economic modeling suggests that surgery would become the preferred strategy only if combined NOM failure during first hospitalization and recurrence rates exceeded 56%.<sup>45</sup> NOM was also the most cost-effective strategy in children, even when considering combined rates of rescue appendectomy for antibiotic-first failure and interval appendectomy set at 41% (which is significantly higher than the 18.3%–35.7% rate reported by recent RCTs). According to the same models, NOM would remain cost-effective up to a 1-year recurrence rate of 32.3%.<sup>46</sup>

Successful antibiotic therapy resulted in an approximate 50% reduction in costs in our meta-analysis (\$ 2509 vs \$ 4898). Surprisingly, even when all appendicitis-related care costs (ie, including antibiotic treatment failure and subsequent surgery, and costs due to management of surgical complications in both groups) were

analyzed, AT represented the most cost-saving option (\$4074 vs \$5117).

Our meta-analysis demonstrated that AT and ST had an equivalent length of primary hospital stay. In non-RCT studies, AT resulted in a significantly shorter length of stay, whereas in RCTs it did not. A possible explanation for these results is that, in the context of experimental trials, patients randomized to NOM with antibiotics have a predetermined length of hospitalization. Indeed, in European trials, patients randomized to antibiotic-first therapy were required to be hospitalized for 3 days, whereas the general trend in the USA is toward shorter hospitalization.<sup>27</sup> Even when analyzing the outcome for patients who required further hospitalizations for treating surgical complications or recurrent episodes of acute appendicitis, the total length of stay did not differ between the 2 groups.

The implementation of treatment and follow-up protocols based on outpatient antibiotic management, and new evidence indicating safety and feasibility of same-day laparoscopic appendectomy for uncomplicated appendicitis may result in optimization of the resource used by reducing inpatient admissions and hospital costs for both nonoperative and surgical treatment in the future.<sup>9,47</sup>

In recent years, there has been a worldwide increase in infections caused by multidrug resistant organisms, as a result of widespread antibiotic use and excessive antimicrobial prescribing practice. In particular, antibiotic regimens that involve the use of ampicillin/sulbactam are no longer recommended because of the increasing rate of β-lactamase producing Escherichia coli, resulting in a reduction in antibiotic susceptibility.<sup>48</sup> Piperacillin-Tazobactam, as well as Penem antibiotics, have been used as first-line antibiotic therapy for patients with uncomplicated appendicitis to address the increasing rate of E coli resistant to third-generation cephalosporins, ampicillin, and amoxicillin.<sup>6,10,27,28</sup> The use of Ertapenem or Meropenem to ensure that most of the bacteria associated with appendicitis-related infection are adequately covered could lead to increased carbapenem resistance, with a major problem in controlling severe infections when they occur, especially in patients with neutropenic sepsis and complicated intra-abdominal infections.

Recently, the results of the study entitled "Randomized clinical trial of antibiotic therapy for uncomplicated appendicitis" by Park et al challenged the need for even antibiotic therapy in uncomplicated appendicitis and reported promising results regarding possible spontaneous resolution in some patients. Analysis of the primary outcome measure indicated that treatment failure rates in patients presenting with CT-confirmed uncomplicated appendicitis were similar among those receiving supportive care with either a noantibiotic regimen or a 4-day course of antibiotics, with no difference in the rates of perforated appendicitis between the 2 groups was reported.<sup>49</sup> Whether recovery from nonperforated appendicitis is the result of antibiotic therapy or natural clinical remission, and so whether antibiotics are superior to simple supportive care for uncomplicated appendicitis remains to be established. If future research demonstrates that antibiotics do not provide any advantage over observation alone in uncomplicated appendicitis, this could have a major impact in reducing the use of antimicrobial agents, especially in this era of increasing antimicrobial resistance worldwide.

This systematic review and meta-analysis is the largest published analysis to date on this topic, with outcomes analyzed for both adult and pediatric populations. In addition, the GRADE methodology has been used to evaluate the quality of the evidence as part of our study. A limitation of our study derives from the difficulty of establishing appropriate endpoints in order to compare such different types of treatment for uncomplicated appendicitis, with mortality being such a rare event and for example, the need for further interventions always going to be lower in the ST group. In our meta-analysis, even taking account of the 14.5% of ST group patients suffering postintervention complications, and the 27.4% of AT group patients experiencing a failure of NOM with antibiotics, both treatment effectiveness and complication-free treatment success rates were better in the ST group, with the obvious advantage that, once the inflamed appendix has been removed, the objective of the complete and long-term avoidance of further appendicitis has been achieved. Nevertheless, NOM with antibiotics might spare a surgical procedure, and thus its potentially related complications, in more than 70% of cases. Little evidence on quality of life or patient experience may also represent relevant limitations.

Another important limitation of the present systematic review with meta-analysis is the small number of well-designed RCTs that have reported on this subject to date, especially regarding pediatric patients. Overall quality of evidence for each of the outcome measures was very low to moderate, and statistical heterogeneity was high for the main outcomes. As diagnostic workup and treatment of uncomplicated appendicitis varies widely across different countries and hospitals, drawing up definitive and universal recommendations on NOM remains elusive. For example, the study by Van Rossem et al showed that preoperative imaging was conducted in 32.8% of UK patients with suspected acute appendicitis, in contrast to 99.5% of patients in the Netherlands.

This led to a large difference in the normal appendectomy rate (20.6% in the UK vs 3.2% in the Netherlands). As NOM for uncomplicated appendicitis requires preoperative imaging, adoption of this approach will require re-evaluation of management algorithms to include imaging in some healthcare systems.<sup>50</sup>

Once considered one of the most significant limitations to the widespread adoption of NOM for uncomplicated appendicitis, the lack of investigation on the long-term clinical efficacy of antibiotics has been addressed in 2018, when Salminen et al published the 5-year follow-up results of the APPAC randomized clinical trial. The authors demonstrated that, among patients who were initially treated with antibiotics for uncomplicated appendicitis, the likelihood of late recurrence within 5 years was 39.1%, with only 2.3% of patients submitted to surgery for recurrent appendicitis diagnosed with complicated forms of the disease, and overall complication rate significantly reduced in the antibiotic group compared to the appendectomy group (6.5% vs 24.4%, P <0.001). This long-term follow-up supported the feasibility of NOM with antibiotics as an alternative to surgery for uncomplicated appendicitis.<sup>51</sup>

As the superiority of one therapy over the other cannot be established due to the fundamental difference of such treatment strategies in the management of uncomplicated appendicitis, further scientific efforts should be focused on the attempt to provide surgeons with clinical, laboratory, and radiological scores which allow the early identification of those patients who might respond well to NOM with antibiotics.

In the meantime, the results of the present meta-analysis may well have the potential to guide and change practice patterns toward more rational and stratified diagnostic and therapeutic pathways, based on current evidence, and avoiding simplistic "one size fits all" approaches.

#### CONCLUSIONS

This study provides evidence required for clinicians to provide evidence-based advice to patients with radiologically confirmed uncomplicated appendicitis regarding both antibiotic therapy and surgical appendectomy as primary treatment options. Patients should be advised that, although limited by a lower efficacy rate compared to surgery, NOM with antibiotics is a safe option for patients keen to avoid appendectomy, and that this approach is successful in the majority of cases. However, patients must also be informed that NOM may fail within 24 to 48 hours in about 8% of cases, and an additional 20% might need a second hospitalization for recurrent AA. NOM for uncomplicated appendicitis does not statistically increase the perforation rate in adult and pediatric patients receiving antibiotic treatment, and the decision to delay appendectomy does not result in increased risk of postoperative complications.

While this systematic review and meta-analysis presents evidence to suggest that NOM with antibiotic is safe and, in most cases, effective, properly powered and well-constructed studies are still required to establish the optimal management strategy for treating uncomplicated appendicitis.

#### REFERENCES

- 1. Gwynn LK. The diagnosis of acute appendicitis: clinical assessment versus computed tomography evaluation. *J Emerg Med.* 2001;21:119–123.
- Ferris M, Quan S, Kaplan BS, et al. The global incidence of appendicitis: a systematic review of population-based studies. *Ann Surg.* 2017;266:237–241.
- Di Saverio S, Birindelli A, Kelly MD, et al. WSES Jerusalem guidelines for diagnosis and treatment of acute appendicitis. *World J Emerg Surg.* 2016;11:34.
- 4. Podda M, Cillara N, Di Saverio S, et al., ACOI (Italian Society of Hospital Surgeons) Study Group on Acute Appendicitis. Antibiotics-first strategy for uncomplicated acute appendicitis in adults is associated with increased rates of peritonitis at surgery. A systematic review with meta-analysis of randomized controlled trials comparing appendectomy and non-operative management with antibiotics. *Surgeon*. 2017;15:303–314.
- Harnoss JC, Zelienka I, Probst P, et al. Antibiotics versus surgical therapy for uncomplicated appendicitis: systematic review and meta-analysis of controlled trials (PROSPERO 2015: CRD42015016882). Ann Surg. 2017;265:889–900.
- Salminen P, Paajanen H, Rautio T, et al. Antibiotic therapy vs appendectomy for treatment of uncomplicated acute appendicitis: the APPAC randomized clinical trial. JAMA. 2015;313:2340–2348.
- Styrud J, Eriksson S, Nilsson I, et al. Appendectomy versus antibiotic treatment in acute appendicitis: a prospective multicenter randomized controlled trial. World J Surg. 2006;30:1033–1037.
- Vons C, Barry C, Maitre S, et al. Amoxicillin plus clavulanic acid versus appendicectomy for treatment of acute uncomplicated appendicitis: an openlabel, non-inferiority, randomised controlled trial. *Lancet*. 2011;377:1573– 1579.
- Talan DA, Saltzman DJ, Mower WR, et al., Olive View–UCLA Appendicitis Study Group. Antibiotics-first versus surgery for appendicitis: a US pilot randomized controlled trial allowing outpatient antibiotic management. *Ann Emerg Med.* 2017;70:1–11.
- Svensson JF, Patkova B, Almström M, et al. Nonoperative treatment with antibiotics versus surgery for acute nonperforated appendicitis in children: a pilot randomized controlled trial. *Ann Surg.* 2015;261:67–71.
- Gorter RR, van der Lee JH, Heijsters FACJ, et al., APAC Study Group. Outcome of initially nonoperative treatment for acute simple appendicitis in children. J Pediatr Surg. 2018;53:1849–1854.
- Gorter RR, Eker HH, Gorter-Stam MA, et al. Diagnosis and management of acute appendicitis. EAES consensus development conference 2015. Surg Endosc. 2016;30:4668–4690.
- Wilms IM, de Hoog DE, de Visser DC, et al. Appendectomy versus antibiotic treatment for acute appendicitis. *Cochrane Database Syst Rev.* 2011;(11):CD008359.
- Sallinen V, Akl EA, You JJ, et al. Meta-analysis of antibiotics versus appendicectomy for non-perforated acute appendicitis. *Br J Surg.* 2016;103: 656–667.
- Findlay JM, Kafsi JE, Hammer C, et al. Nonoperative management of appendicitis in adults: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Surg. 2016;223:814–824.
- Sakran JV, Mylonas KS, Gryparis A, et al. Operation versus antibiotics—the "appendicitis conundrum" continues: a meta-analysis. J Trauma Acute Care Surg. 2017;82:1129–1137.
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. 2009;339:b2700.

12 | www.annalsofsurgery.com

© 2019 Wolters Kluwer Health, Inc. All rights reserved.

- Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012.
- Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.3.5. The Cochrane Collaboration, 2014. Available at www.handbook.cochrane.org. Accessed August 2018.
- Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*. 2016;355:i4919.
- 21. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol*. 2011;64:401–406.
- Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
- Eriksson S, Granström L. Randomized controlled trial of appendicectomy versus antibiotic therapy for acute appendicitis. *Br J Surg.* 1995;82:166–169.
- 25. Turhan AN, Kapan S, Kutukcu E, et al. Comparison of operative and non operative management of acute appendicitis. *TJTES*. 2009;15:459–462.
- Park HC, Kim MJ, Lee BH. The outcome of antibiotic therapy for uncomplicated appendicitis with diameters ≤ 10 mm. *Int J Surg.* 2014;12:897–900.
- Minneci PC, Mahida JB, Lodwick DL, et al. Effectiveness of patient choice in nonoperative vs surgical management of pediatric uncomplicated acute appendicitis. *JAMA Surg.* 2016;151:408–415.
- Hartwich J, Luks FI, Watson-Smith D, et al. Nonoperative treatment of acute appendicitis in children: a feasibility study. J Pediatr Surg. 2016;51:111–116.
- 29. Mahida JB, Lodwick DL, Nacion KM, et al. High failure rate of nonoperative management of acute appendicitis with an appendicolith in children. *J Pediatr Surg.* 2016;51:908–911.
- Tanaka Y, Uchida H, Kawashima H, et al. Long-term outcomes of operative versus nonoperative treatment for uncomplicated appendicitis. *J Pediatr Surg.* 2015;50:1893–1897.
- Allievi N, Harbi A, Ceresoli M, et al. Acute appendicitis: still a surgical disease? Results from a propensity score-based outcome analysis of conservative versus surgical management from a prospective database. World J Surg. 2017;41:2697–2705.
- Lee SL, Spence L, Mock K, et al. Expanding the inclusion criteria for nonoperative management of uncomplicated appendicitis: outcomes and cost. *J Pediatr Surg.* 2017 [Epub ahead of print].
- Armstrong J, Merritt N, Jones S, et al. Non-operative management of early, acute appendicitis in children: is it safe and effective? J Pediatr Surg. 2014;49:782–785.
- 34. Koike Y, Uchida K, Matsushita K, et al. Intraluminal appendiceal fluid is a predictive factor for recurrent appendicitis after initial successful non-operative management of uncomplicated appendicitis in pediatric patients. *J Pediatr Surg.* 2014;49:1116–1121.
- Mudri M, Coriolano K, Bütter A. Cost analysis of nonoperative management of acute appendicitis in children. J Pediatr Surg. 2017;52:791–794.

- 36. Poillucci G, Mortola L, Podda M, et al. ACTUAA-R Collaborative Working Group on Acute Appendicitis. Laparoscopic appendectomy vs antibiotic therapy for acute appendicitis: a propensity score-matched analysis from a multicenter cohort study. *Updates Surg.* 2017;69:531–540.
- Hansson J, Körner U, Khorram-Manesh A, et al. Randomized clinical trial of antibiotic therapy versus appendicectomy as primary treatment of acute appendicitis in unselected patients. *Br J Surg.* 2009;6:473–481.
- Telem DA. Shared decision making in uncomplicated appendicitis: it is time to include nonoperative management. JAMA. 2016;315:811–812.
- Hanson AL, Crosby RD, Basson MD. Patient preferences for surgery or antibiotics for the treatment of acute appendicitis. *JAMA Surg.* 2018;153:471– 478.
- Hansson J, Khorram-Manesh A, Alwindawe A, et al. A model to select patients who may benefit from antibiotic therapy as the first line treatment of acute appendicitis at high probability. J Gastrointest Surg. 2014;18:961–967.
- Loftus TJ, Brakenridge SC, Croft CA, et al. Successful nonoperative management of uncomplicated appendicitis: predictors and outcomes. J Surg Res. 2018;222:212–218.
- van Dijk ST, van Dijk AH, Dijkgraaf MG, et al. Meta-analysis of in-hospital delay before surgery as a risk factor for complications in patients with acute appendicitis. *Br J Surg.* 2018;105:933–945.
- Gorter RR, The SML, Gorter-Stam MAW, et al. Systematic review of nonoperative versus operative treatment of uncomplicated appendicitis. J Pediatr Surg. 2017;52:1219–1227.
- Verma R, Grechushkin V, Carter D, et al. Use and accuracy of computed tomography scan in diagnosing perforated appendicitis. *Am Surg.* 2015;81:404–407.
- 45. Wu JX, Dawes AJ, Sacks GD, et al. Cost effectiveness of nonoperative management versus laparoscopic appendectomy for acute uncomplicated appendicitis. *Surgery*. 2015;158:712–721.
- 46. Wu JX, Sacks GD, Dawes AJ, et al. The cost-effectiveness of nonoperative management versus laparoscopic appendectomy for the treatment of acute, uncomplicated appendicitis in children. *J Pediatr Surg.* 2017;52:1135–1140.
- Farach SM, Danielson PD, Walford NE, et al. Same-day discharge after appendectomy results in cost savings and improved efficiency. *Am Surg.* 2014;80:787–791.
- Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. *Lancet Infect Dis.* 2008;8:159–166.
- Park HC, Kim MJ, Lee BH. Randomized clinical trial of antibiotic therapy for uncomplicated appendicitis. Br J Surg. 2017;104:1785–1790.
- 50. van Rossem CC, Bolmers MD, Schreinemacher MH, et al. Diagnosing acute appendicitis: surgery or imaging? *Colorectal Dis.* 2016;18:1129–1132.
- Salminen P, Tuominen R, Paajanen H, et al. Five-year follow-up of antibiotic therapy for uncomplicated acute appendicitis in the APPAC randomized clinical trial. *JAMA*. 2018;320:1259–1265.

© 2019 Wolters Kluwer Health, Inc. All rights reserved.

www.annalsofsurgery.com | 13